Antibodies that specifically recognize Pseudomonas (Psl) and their use

Abstract

To provide isolated antibodies that specifically bind to Pseudomonas Psl or antigen-binding fragments, and methods of using them for preventing and treating Pseudomonas infections.SOLUTION: Provided herein are antibodies including antigen-binding fragments that specifically bind to Pseudomonas Psl. Also provided are methods of making and using these antibodies.SELECTED DRAWING: None

Description

[Technical Field]

[0001] This invention relates to Pseudomonas aeruginosa (PA) Psl. This relates to antibodies that specifically recognize such antibodies, methods for preparing them, and their use, and such use may involve... This includes methods for treating and preventing Pseudomonas infections. [Background technology]

[0002] Pseudomonas aeruginosa is a commonly found, obligate aerobic, Gram-negative bacillus. Although it has low pathogenicity, it is a pathogen that causes opportunistic infections, so Pseudomonas aeruginosa infections can lead to cancer, sugar, and other diseases. Patients with various pre-existing conditions such as urinary tract diseases and immunodeficiency, and those receiving immunosuppressive drugs It frequently occurs in patients with ruptured skin and mucous membranes, and, There is also a considerable risk for patients with chronic structural lung diseases (e.g., chronic obstructive pulmonary disease and cystic fibrosis). There is a risk. Pseudomonas aeruginosa often causes pneumonia, urinary tract infections, sepsis, and other serious complications. This often leads to consequences. Up to 10% of hospital infections are caused by Pseudomonas aeruginosa. The mortality rate for patients with Pseudomonas aeruginosa bacteremia is approaching 40%. In the clinical field, Pseudomonas aeruginosa bacteremia Pseudomonas aeruginosa is considered one of the most difficult infections to treat. Pseudomonas aeruginosa itself is not treated with existing antibiotics. This is because, in addition to having low susceptibility to it, it tends to have high resistance to various antibiotics. Yes. Therefore, the strategy of developing antibiotics has advantages in dealing with Pseudomonas aeruginosa infections. It is limited.

[0003] Pseudomonas aeruginosa is one of the leading causes of acquired infections in hospitals, especially in mechanically ventilated patients. It is one of the leading causes of death in patients with cystic fibrosis. Pseudomonas aeruginosa biofilm matrix One important component is the protein encoded by the polysaccharide synthesis gene locus. The resulting Psl polysaccharide may be released extracellularly and may also bind to the cell surface. That is also fine. The structure of Psl released extracellularly is D-mannose, L-rhamnose, and It is composed of repeating pentasaccharides containing D-glucose. Psl is present during biofilm formation. It possesses both structural and protective functions, and the biofilm is protected by antibiotics (chemical bonding). It is also known that it can protect against (by) and the immune system (by an unknown mechanism). Therefore, it could be an ideal target for new treatment options (Ray VA. et al.). al. Anti-Psl Targeting of Pseudomonas ae ruginosa Biofilms for Neutrophil-Mediate d Disruption. Sci Rep. 2017). (DiGiandomen ico, A. et al. Identification of broadly protective human antibodies to pseudomo nas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 209, 127 3-1287; Valerie A. Ray, et al, Anti-Psl targeting of Pseudomonas aeruginosa biof ilms for neutrophil mediated disruption, Scientific Reports7, Article number:160 65(2017)) describes human monoclonal antibodies (mAbs) that target Psl, for example Wapr-001, Wapr-016, Cam-003 or their derivatives psl00 96 is listed.

[0004] All publications, patents, patent applications and published patent applications referred to herein The content described herein is incorporated in its entirety by reference. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Ray VA. et al. Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption. Sci Rep.2017 [Non-Patent Document 2] DiGiandomenico, A. et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 209, 1273-1287 [Non-Patent Document 3] Valerie A. Ray, et al, Anti-Psl targeting of Pseudomonas aeruginosa biofilms for neutrophil mediated disruption, Scientific Reports7, Article number:16065(2017) [Overview of the project] [Problems that the invention aims to solve]

[0006] This invention relates to isolated antibodies or antigens that specifically bind to Pseudomonas (Psl) species. Sexual fragments and methods for using them in the prevention and treatment of Pseudomonas infections provide. [Means for solving the problem]

[0007] In one aspect of the present invention, V H Isolated organisms that specifically bind to Pseudomonas species Psl, including [specific organisms]. An antibody or antigen-binding fragment, wherein V H SEQ ID NOs:2 -3 and 5-12, each comprising one amino acid sequence or a variant thereof, and the mutation One HC-CDR1, which contains at most three amino acid substitutions, and SEQ I D NOs: One amino acid sequence or variant of 14-15 and 17-23 One HC-C molecule containing a variant, the aforementioned variant containing at most three amino acid substitutions. DR2 and one of the following SEQ ID NOs: 25-26 and 28-34 A sequence containing no-acid sequences or their variants, wherein the variant contains at most three amino acid substitutions. An isolation compound containing one HC-CDR3 that specifically binds to Pseudomonas genus Psl. Provides an antibody or antigen-binding fragment.

[0008] In one aspect of the present invention, V L Isolated organisms that specifically bind to Pseudomonas species Psl, including An antibody or antigen-binding fragment, wherein V L SEQ ID NOs:3 It comprises one amino acid sequence or variant thereof, either 8-39 or 41-49, prior One LC-CDR1 variant containing at most three amino acid substitutions, and SE Q ID NOs: Any one amino acid sequence of 52-53 and 55-61 or One L containing the mutant, wherein the mutant contains at most three amino acid substitutions. C-CDR2 and SEQ ID NOs: 63-64, 66-68, and 70-75 It contains any one amino acid sequence or a variant thereof, and the variant has at most three amino acids. Pseudomonas Psl and a specific LC-CDR3 containing an acid substitution This invention provides isolated antibodies or antigen-binding fragments that bind heterologously.

[0009] In one aspect of the present invention, V H and V L It specifically binds to Pseudomonas species Psl, including [specific Pseudomonas species]. An isolated antibody or antigen-binding fragment, wherein V H is SEQ ID NOs: Containing one amino acid sequence or variant thereof from 2-3 and 5-12 , one HC-CDR1 having at most three amino acid substitutions, SEQ ID NOs: One amino acid sequence from either 14-15 or 17-23 or a variant thereof, and one of the aforementioned variants contains at most three amino acid substitutions. HC-CDR2 and either SEQ ID NOs: 25-26 or 28-34 It contains one amino acid sequence or a variant thereof, and the variant has at most three amino acid substitutions. Includes one HC-CDR3 which contains the V L SEQ ID NOs: It comprises one of the amino acid sequences 38-39 and 41-49 or a variant thereof, The aforementioned mutant contains at most three amino acid substitutions in one LC-CDR1, and S EQ ID NOs: Any one amino acid sequence from 52-53 and 55-61 or comprising the variant, wherein the variant comprises at most 3 amino acid substitutions, one LC-CDR2 and any one of the amino acid sequences of SEQ ID NOs: 63-64, 66-68, and 70-75 or a variant thereof, wherein the variant comprises at most 3 amino acid substitutions, and one LC-CDR3, and provides an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl. In one aspect of the present invention, (i) comprising V

[0010] wherein the V H comprises one HC-CDR1 comprising the amino acid sequence SEQ ID N H O:2, one HC-CDR2 comprising the amino acid sequence SEQ ID NO: 14, and one HC-CD R3 comprising the amino acid sequence SEQ ID NO: 25, or a variant comprising at most 5 amino acid substitutions in the HC-CDRs comprises, (ii) V wherein the V comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO: 3, one HC-CDR2 H comprising the amino acid sequence SEQ ID NO: 15, and one HC-CDR3 comprising the amino acid sequence SEQ ID NO: 26, and H also comprises a variant comprising at most 5 amino acid substitutions in the HC-CDRs, (iii) V comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO: 5, one HC-CDR2 comprising the amino acid sequence SEQ ID NO: 17, and one HC-CDR3 comprising the amino acid sequence SEQ ID NO: 28, or a variant comprising at most 5 amino acid substitutions in the HC-CDRs, (iv) V H comprises, wherein the V comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO: 5, H one HC-CDR2 comprising the amino acid sequence SEQ ID NO: 17, and one HC-CDR3 comprising the amino acid sequence SEQ ID NO: 28, or a variant comprising at most 5 amino acid substitutions in the HC-CDRs, (iv) V comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO: 5, one HC-CDR2 comprising the amino acid sequence SEQ ID NO: 17, and one HC-CDR3 comprising the amino acid sequence H comprises the V Hteeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:6, and amino acid sequence SE One HC-CDR2 containing Q ID NO:18 and amino acid sequence SEQ ID NO :Includes one HC-CDR3 containing 29, or HC-CDRs containing at most 5 A Includes mutants containing mino acid substitutions, (v)V H Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:7 and amino acid sequence SEQ ID NO:14 One HC-CDR2 containing and one H containing amino acid sequence SEQ ID NO:25 Mutations containing C-CDR3 or HC-CDRs containing at least 5 amino acid substitutions (vi)V H Including the above V H It contains amino acid sequence SEQ ID NO:8 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:19 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:30. or include mutants containing at most 5 amino acid substitutions in HC-CDRs, (vii )V H Including the above V H This contains one HC-C amino acid sequence SEQ ID NO:3. DR1, one HC-CDR2 containing amino acid sequence SEQ ID NO:15, and ami It contains one HC-CDR3 containing the noacid sequence SEQ ID NO:26, or HC- CDRs include mutants containing at most 5 amino acid substitutions, (viii)V H Includes, The aforementioned V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:9, and One HC-CDR2 containing the no-acid sequence SEQ ID NO:20, and the amino acid sequence SEQ Includes one HC-CDR3 containing ID NO:31, or many HC-CDRs. Both include mutants containing 5 amino acid substitutions, (ix)V H Including the above V H is, amino One HC-CDR1 containing the acid sequence SEQ ID NO:10, and the amino acid sequence SEQ One HC-CDR2 containing ID NO:21 and amino acid sequence SEQ ID NO:3 It contains one HC-CDR3 containing 2, or HC-CDRs containing at most 5 amino acids Includes mutants with acid substitution, (x)V H Including the above V H This is the amino acid sequence SEQ ID One HC-CDR1 containing NO:11 and amino acid sequence SEQ ID NO:22 It contains one HC-CDR2 and one HC containing amino acid sequence SEQ ID NO:33 Mutants containing -CDR3 or containing at least 5 amino acid substitutions in HC-CDRs including, or (xi)V H Including the above V H The amino acid sequence SEQ ID NO: One HC-CDR1 containing 12 and one containing amino acid sequence SEQ ID NO:23 HC-CDR2 and one HC-CDR containing amino acid sequence SEQ ID NO:34 3 and includes, or includes mutants in which HC-CDRs have at least 5 amino acid substitutions, Isolated antibodies or antigen-binding fragments that specifically bind to Pseudomonas Psl. We will provide the product.

[0011] In one aspect of the present invention, (i)V L Including the above V L This is the amino acid sequence SEQ ID N Contains one LC-CDR1 with O:38 and amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC-C containing amino acid sequence SEQ ID NO:63 Contains DR3 or mutants containing at most 5 amino acid substitutions in LC-CDRs. (ii)V L Including the above V L This includes amino acid sequence SEQ ID NO:39. One LC-CDR1 and one LC-CD containing amino acid sequence SEQ ID NO:53 It contains R2 and one LC-CDR3 containing the amino acid sequence SEQ ID NO:64, Alternatively, the LC-CDRs may contain mutants with at most 5 amino acid substitutions, (iii)V L Including the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:41 R1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and amino It contains one LC-CDR3 containing acid sequence SEQ ID NO:66, or LC-C DRs include mutants with at most 5 amino acid substitutions, (iv)V L Including the above V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:42, and amino acids One LC-CDR2 containing sequence SEQ ID NO:55 and amino acid sequence SEQ I Includes one LC-CDR3 containing D NO:67, or at least one LC-CDRs. Includes a mutant containing 5 amino acid substitutions, (v)V L Including the above V L The amino acid sequence One LC-CDR1 containing SEQ ID NO:43, and amino acid sequence SEQ ID Contains one LC-CDR2 with NO:56 and amino acid sequence SEQ ID NO:68 It contains one LC-CDR3 or at most five amino acid substitutions in the LC-CDRs. Includes variants containing (vi)V L Including the above V L This is the amino acid sequence SEQ ID N One LC-CDR1 containing O:44 and amino acid sequence SEQ ID NO:57 One LC-CDR2 and one LC-C containing amino acid sequence SEQ ID NO:70 Contains DR3 or mutants containing at most 5 amino acid substitutions in LC-CDRs. Mi, (vii)V L Including the above V L This includes amino acid sequence SEQ ID NO:45 One LC-CDR1 and one LC-C containing amino acid sequence SEQ ID NO:58 It contains DR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:71. , or include mutants in which LC-CDRs contain at most 5 amino acid substitutions, (viii )V L Including the above V L This is one LC- containing amino acid sequence SEQ ID NO:46 CDR1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:52, and It contains one LC-CDR3 containing the mino acid sequence SEQ ID NO:72, or LC -CDRs include mutants with at most 5 amino acid substitutions, (ix)V L Including, before Record V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:47, and One LC-CDR2 containing the amino acid sequence SEQ ID NO:59, and the amino acid sequence SEQ Includes one LC-CDR3 containing ID NO:73, or many LC-CDRs. Both include mutants containing 5 amino acid substitutions, (x)V L Including the above V L amino acids One LC-CDR1 containing sequence SEQ ID NO:48 and amino acid sequence SEQ I One LC-CDR2 containing D NO:60 and amino acid sequence SEQ ID NO:74 It contains one LC-CDR3 containing, or LC-CDRs containing at most five amino acids Includes variants with substitutions, or (xi)V L Including the above V L This is the amino acid sequence SE One LC-CDR1 containing Q ID NO:49 and amino acid sequence SEQ ID NO One LC-CDR2 containing :61 and one containing amino acid sequence SEQ ID NO:75 It contains one LC-CDR3 or the LC-CDRs contain at most five amino acid substitutions. Isolated antibodies or antigens that specifically bind to Pseudomonas genus Psl, including variants. Provides a binding fragment.

[0012] In one aspect of the present invention, (i)V H and V L Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:2 and amino acid sequence SEQ ID NO:1 One HC-CDR2 containing 4 and one containing amino acid sequence SEQ ID NO:25 Modified HC-CDR3 containing or containing at most 5 amino acid substitutions in HC-CDRs Including a different body, the V L This is one LC-C containing amino acid sequence SEQ ID NO:38 DR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and It contains one LC-CDR3 containing the noacid sequence SEQ ID NO:63, or LC- The CDRs include mutants containing at most 5 amino acid substitutions, (ii)V H and V L of Including the aforementioned V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:3 and , one HC-CDR2 containing amino acid sequence SEQ ID NO:15, and amino acid sequence Includes one HC-CDR3 containing SEQ ID NO:26, or HC-CDRs The V includes a mutant containing at least 5 amino acid substitutions, L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:39 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 3 and one containing amino acid sequence SEQ ID NO:64 Modified LC-CDR3 containing or containing at most 5 amino acid substitutions in LC-CDRs (iii)V H and V L Including the above V H This is the amino acid sequence SEQ ID Contains one HC-CDR1 including NO:5 and amino acid sequence SEQ ID NO:17 One HC-CDR2 and one HC- containing amino acid sequence SEQ ID NO:28 A mutant containing CDR3 or containing at least 5 amino acid substitutions in HC-CDRs Including the aforementioned V L This is one LC-CDR1 containing amino acid sequence SEQ ID NO:41 And, one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and amino acid Includes one LC-CDR3 containing column SEQ ID NO:66, or LC-CDR (iv)V H and V L Includes, The aforementioned V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:6, and One HC-CDR2 containing the amino acid sequence SEQ ID NO:18, and the amino acid sequence SEQ Includes one HC-CDR3 containing ID NO:29, or many HC-CDRs. Both include mutants containing 5 amino acid substitutions, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:42 and amino acid sequence SEQ ID NO:55 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:67 A mutant containing CDR3 or LC-CDRs containing at least 5 amino acid substitutions (v)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:7 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:14 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:25 The above includes, or includes a variant in which the HC-CDRs have at least 5 amino acid substitutions. V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:43, and amino One LC-CDR2 containing the acid sequence SEQ ID NO:56, and the amino acid sequence SEQ Includes one LC-CDR3 containing ID NO:68, or many LC-CDRs It also includes mutants containing 5 amino acid substitutions, (vi)V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:8, and amino acid sequence S One HC-CDR2 containing EQ ID NO:19 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:30, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V LThis is the amino acid sequence SEQ ID NO:44 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:57 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:70 It includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions, (v ii)V H and V L Including the above V H This includes amino acid sequence SEQ ID NO:3 One HC-CDR1 and one HC-C containing amino acid sequence SEQ ID NO:15 It contains DR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:26. , or a variant containing at most 5 amino acid substitutions in HC-CDRs, and the V L teeth , one LC-CDR1 containing amino acid sequence SEQ ID NO:45, and amino acid sequence One LC-CDR2 containing SEQ ID NO:58 and amino acid sequence SEQ ID Includes one LC-CDR3 containing NO:71, or at most 5 LC-CDRs Includes mutants containing amino acid substitutions, (viii)V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:9, and amino acid sequence SE One HC-CDR2 containing Q ID NO:20 and amino acid sequence SEQ ID NO :31 contains one HC-CDR3 and, or HC-CDRs contain at most 5 A The variant includes a mutant containing a mino acid substitution, and the V L The amino acid sequence SEQ ID NO:46 It contains one LC-CDR1 and one LC containing amino acid sequence SEQ ID NO:52 - a CDR2 and one LC-CDR3 comprising the amino acid sequence SEQ ID NO:72 comprising, or comprising a variant comprising at most 5 amino acid substitutions in the LC-CDRs, (ix )V H and V L comprising, wherein said V H comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO:10, one HC-CD R2 comprising the amino acid sequence SEQ ID NO:21, and one HC-CDR3 comprising the amino acid sequence SEQ ID NO:32, or comprising a variant comprising at most 5 amino acid substitutions in the HC-CDRs, wherein said V comprises one LC-CDR1 comprising the amino acid sequence SEQ ID NO:47, one LC-CDR2 comprising the amino acid S L [[ID=1-eight]]is, EQ ID NO:59, and one LC-CDR3 comprising the amino acid sequence SEQ ID NO:73, or comprising at most 5 amino acid substitutions in the LC-CDRs, (x)V and V comprising, wherein said V H comprises one HC-CDR1 comprising the amino acid sequence SEQ ID NO:ll, one HC-CDR2 comprising the amino acid I L D NO:22, and one HC-CDR3 comprising the amino acid sequence SEQ ID NO:33 H comprising, or comprising a variant comprising at most 5 amino acids substitutions in the HC-CDRs, wherein said V comprises one LC-CDR1 comprising the amino acid sequence SEQ ID NO:48, one LC-CDRl comprising the amino acid sequence SEQ ID NO:60 and one LC-CDR3 comprising the amino acid sequence SEQ ID NO:74, or comprising at most 5 amino acids ​​​​​​​​​​​H and V L comprising, wherein said V H comprises an amino acid sequence SEQ ID NO:12 one HC-CDR1 comprising an amino acid sequence SEQ ID NO:23, and one HC-C DR2 comprising an amino acid sequence SEQ ID NO:34, and one HC-CDR3 comprising an amino acid sequence SEQ ID NO:34, or variants comprising at most 5 amino acid substitutions in the HC-CDRs, wherein said V L is one LC-CDR1 comprising an amino acid sequence SEQ ID NO:49, an amino acid sequence SEQ ID NO:61, and one LC-CDR3 comprising an amino acid sequence SEQ ID NO:75, or variants comprising at most 5 amino acid substitutions in the LC-CDRs, and provides an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl.

[0013] In one aspect of the invention, V H and V L comprising, wherein said V H has an amino acid sequence of any one of SEQ ID NOs:8 0-81, 83-90, and 159, and comprises HC-CDR1, HC-CDR2 and HC-CDR3 in V H wherein said V has an amino acid sequence of any one of SEQ ID NOs:92-93, 95-97, and 99-104 in V L and comprises LC-CDR1, LC-CDR2 and LC-CDR3 in V and provides an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl. L fragment.

[0014] In one aspect of the invention, V H and V​​​L Including the above V H SEQ ID NOs:8 One of the amino acid sequences 0-81, 83-90, and 159, or SEQ I D NOs: One of the amino acid sequences 80-81, 83-90, and 159 and a small amount At least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%) The variant sequence has 97%, 98%, or 99% sequence identity, and the V L is, S EQ ID NOs: One of the following: 92-93, 95-97, and 99-104 Mino acid sequence, or SEQ ID NOs: 92-93, 95-97, and 99-10 4. Any one amino acid sequence and at least 90% (e.g., at least 91%, 92%) It has sequence identity of 93%, 94%, 95%, 96%, 97%, 98%, or 99%. An isolated antibody containing a mutant sequence that specifically binds to Pseudomonas Psl or It provides antigen-binding fragments.

[0015] In one aspect of the present invention, V H and V L Including the above V H SEQ ID NOs:8 The amino acid sequence comprises one of the following: 0-81, 83-90, and 159, and the V L teeth SEQ ID NOs: One of 92-93, 95-97, and 99-104 An isolated antibody containing the amino acid sequence of Pseudomonas Psl that specifically binds to the genus Pseudomonas, It provides an antigen-binding fragment.

[0016] In one aspect of the present invention, (i) V containing amino acid sequence SEQ ID NO:80 H and V containing amino acid sequence SEQ ID NO:92 L (ii) Amino acid sequence SEQ I V including D NO:81 H and V containing amino acid sequence SEQ ID NO:93 L ; (iii) V containing amino acid sequence SEQ ID NO:83 H and amino acid sequence SE V including Q ID NO:95 L (iv) Contains amino acid sequence SEQ ID NO:84 Mu V H and V containing amino acid sequence SEQ ID NO:96 L (v) Amino acid sequence V including SEQ ID NO:85 H and amino acid sequence SEQ ID NO:97 Includes V L (vi) V containing amino acid sequence SEQ ID NO:86 H and amino acid blends V containing column SEQ ID NO:99 L (vii) Amino acid sequence SEQ ID NO :81 including V H and V containing amino acid sequence SEQ ID NO:100 L ;(vi ii) V containing amino acid sequence SEQ ID NO:87 H and amino acid sequence SEQ V containing ID NO:101 L (ix) Contains amino acid sequence SEQ ID NO: 88 V H and V containing amino acid sequence SEQ ID NO:102 L (x) Amino acid sequence V including SEQ ID NO:89 H and amino acid sequence SEQ ID NO:103 V including L ;(xi)V containing amino acid sequence SEQ ID NO:90 H and amino acids V containing sequence SEQ ID NO:104L ; or (xii) amino acid sequence SEQ V including ID NO:159 H and V containing amino acid sequence SEQ ID NO:95 L Isolated antibodies or antigen-binding antibodies that specifically bind to Pseudomonas species Psl, including , Provides fragments.

[0017] In one aspect of the present invention, the heavy chain variable domain (V H ) and light chain variable domain (V L ) including M, the aforementioned V H This includes IHSVH (SEQ ID NO: 4) or its variants, and the above A single heavy chain complementarity-determining region (HC) that contains at most three amino acid substitutions. -CDR)1 and TIISSGTTTTYAQSFQD(SEQ ID NO:16) or a variant thereof, and one of the aforementioned variants contains at most three amino acid substitutions. HC-CDR2 and X1X2X3X4 (SEQ ID NO:189) or its variants The mutant includes a body and contains at most three amino acid substitutions, where X1 is D, Y or N, X2 is G or A, X3 is D or T, X4 is S, Includes one HC-CDR3 which is A or T, and the V L RASQGISSWLA (SEQ ID NO:40) or its variants, and the said variants include at most 3 A One light chain complementarity determination region (LC-CDR)1 containing a mino acid substitution, and HAST Includes LES (SEQ ID NO: 54) or its variants, and the variants number at most 3 One LC-CDR2 containing one amino acid substitution and LQAX1SLPHT(S EQ ID NO:158) or its variants, and the variants contain at most 3 ami This includes no acid substitutions, where X1 is N, D, Y, F, P, G, K, H, A, C, Pseudomonas include one LC-CDR3 which is E, Q, R, S, T, V, W, or L. This provides isolated antibodies or antigen-binding fragments that specifically bind to Solanum species Psl. ru.

[0018] In one aspect of the present invention, the heavy chain variable domain (V H ) and light chain variable domain (V L ) including M, the aforementioned V H This is a single heavy chain complementarity determination region containing IHSVH (SEQ ID NO: 4). Region (HC-CDR)1 and TIISSGTTTTYAQSFQD(SEQ ID NO: 16) One HC-CDR2 including SEQ ID NO: 27, SEQ ID NO :35, amino acid sequence selected from the group consisting of SEQ ID NOs:165-169 Includes one HC-CDR3 containing the V L is RASQGISSWLA(SEQ One light chain complementarity determination region (LC-CDR) 1 (ID NO: 40) and HASTL One LC-CDR2 containing ES (SEQ ID NO: 54), and SEQ ID NO :65, SEQ ID NOs:76-78, and SEQ ID NOs:199-2 A shrunk LC-CDR3 containing an amino acid sequence selected from a group of 12 Isolated antibodies or antigen-binding fragments that specifically bind to the genus Domonas Psl provide.

[0019] In one aspect of the present invention, (i)V H and V L Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:4 and amino acid sequence SEQ ID NO:1 One HC-CDR2 containing 6 and one containing amino acid sequence SEQ ID NO:27 Modified HC-CDR3 containing or containing at most 5 amino acid substitutions in HC-CDRs Including a different body, the V L This is one LC-C containing amino acid sequence SEQ ID NO:40 DR1, one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and It contains one LC-CDR3 containing the noacid sequence SEQ ID NO:65, or LC- The CDRs include mutants containing at most 5 amino acid substitutions, (ii)V H and V L of Including the aforementioned V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:4 and , one HC-CDR2 containing amino acid sequence SEQ ID NO:16, and amino acid sequence Includes one HC-CDR3 containing SEQ ID NO:35, or HC-CDRs The V includes a mutant containing at least 5 amino acid substitutions, L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:40 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 4 and one containing amino acid sequence SEQ ID NO:78 Modified LC-CDR3 containing or containing at most 5 amino acid substitutions in LC-CDRs (iii)V H and V L Including the above V H This is the amino acid sequence SEQ ID Contains one HC-CDR1 with NO:4 and amino acid sequence SEQ ID NO:16 One HC-CDR2 and one HC- containing amino acid sequence SEQ ID NO:35 A mutant containing CDR3 or containing at least 5 amino acid substitutions in HC-CDRs Including the aforementioned V L This is one LC-CDR1 containing amino acid sequence SEQ ID NO:40 And, one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid Includes one LC-CDR3 containing column SEQ ID NO:76, or LC-CDR The mutant contains at most 5 amino acid substitutions in s, or (iv)V H and V L Including the above V H This is one HC-CDR1 containing amino acid sequence SEQ ID NO:4 And, one HC-CDR2 containing amino acid sequence SEQ ID NO:16, and amino acid Includes one HC-CDR3 containing column SEQ ID NO:35, or HC-CDR The mutant includes at most 5 amino acid substitutions in s, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:40, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 54 and one containing amino acid sequence SEQ ID NO:77 It contains LC-CDR3 or LC-CDRs containing at most 5 amino acid substitutions. Isolated antibodies or antigens that specifically bind to Pseudomonas Psl, including mutants. Provides compatible fragments.

[0020] In one aspect of the present invention, (i)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:82 and at least 90% (For example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) or includes a variant sequence having sequence identity of 99%, and the V L This is the amino acid sequence SE Q ID NO:94, or amino acid sequence SEQ ID NO:94 and at least 90 % (for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) (ii)V H and V L Includes M, the aforementioned V H This is one of the amino acid sequences SEQ ID NOs:105-110 , or one amino acid sequence from SEQ ID NOs: 105-110 and less All 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%) The variant sequence has sequence identity of %, 98%, or 99%, and the V L is, amino Acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID NO:94 and a small number at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 9) (iii)V H oh Call V L Including the above V H This is the amino acid sequence SEQ ID NO:82, or amino acid Sequence SEQ ID NO:82 and at least 90% (e.g., at least 91%, 92%) It has sequence identity of 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The variant sequence is included, and the V L This is one of the SEQ ID NOs: 111-127 The amino acid sequence of, or any one of the amino acids in SEQ ID NOs: 111-127 Acid sequence and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes a mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, (i v)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:107, or amino acid sequence SEQ ID NO:107 and at least 90% (for example, at least 9 Arrays of 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) Includes a variant sequence having identity, and the V L This is the amino acid sequence SEQ ID NO:11 3. Or amino acid sequence SEQ ID NO:113 and at least 90% (e.g., less (91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) It contains a mutant sequence having sequence identity, (v)V H and V L Including the above V H is, amino acid sequence SEQ ID NO:107, or amino acid sequence SEQ ID NO:10 7 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 123, or amino acid sequence SEQ ID NO :123 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes mutant sequences having sequence identity of %, 96%, 97%, 98%, or 99%, and taha(vi)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:1 07, or amino acid sequence SEQ ID NO:107 and at least 90% (for example, less At least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% The variant sequence having sequence identity of the V L This is the amino acid sequence SEQ ID N O:116, or amino acid sequence SEQ ID NO:116 and at least 90% (for example) or at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or A mutant sequence containing 99% sequence identity is specifically linked to Pseudomonas genus Psl. Provides a binding isolated antibody or antigen-binding fragment.

[0021] In one aspect of the present invention, the heavy chain variable domain (V H ) and light chain variable domain (V L ) including M, the aforementioned V H This includes SSGDYWG (SEQ ID NO:1) or its variants. The aforementioned mutant contains at most three amino acid substitutions in one heavy chain complementarity-determining region ( HC-CDR)1 and SIHNX1GSTYYNPSLKG(SEQ ID NO:21 3) Including a variant thereof, the variant containing at most three amino acid substitutions Here, X1 is one HC-CDR2 which is S, K, or Q, and QFGSETYYX It contains 1GIX2P (SEQ ID NO: 190) or its variants, and the variants are numerous. It contains at least three amino acid substitutions, where X1 is N, S, V, T, or P. Yes, X2 is one H which is D, Y, C, H, S, R, A, E, G, K, W, V or Q Includes C-CDR3 and the V L is RSSQSLLHSX1GYNYLD(SEQ I D NO:184) or its variants, the variants having at most three amino acid substitutions. This includes, where X1 is N, A, V, F, R, G, H, Q, W, or P. One light chain complementarity determination region (LC-CDR)1 and LGSNRAS (SEQ ID NO :51) or a variant thereof, wherein the variant contains at most three amino acid substitutions. One LC-CDR2 and MQALQTPX1T (SEQ ID NO:214) or a variant thereof, the variant having at most three amino acid substitutions, Here, X1 is a Pseudomonas Ps with one LC-CDR3, which is either R or Y. The present invention provides an isolated antibody or antigen-binding fragment that specifically binds to l.

[0022] In one aspect of the present invention, the heavy chain variable domain (V H ) and light chain variable domain (V L ) including M, the aforementioned V H This is a single heavy chain complementary denominator containing SSGDYWG (SEQ ID NO:1). Fixed region (HC-CDR) 1, SEQ ID NO: 13, and SEQ ID NOs :One HC-CDR2 containing an amino acid sequence selected from the group consisting of 163-164 and , SEQ ID NO:24, SEQ ID NO:36, SEQ ID NOs:17 Selected from the group consisting of 0-183 and SEQ ID NOs:185-188. The V L SEQ ID NO:3 7. SEQ ID NO: 50, and SEQ ID NOs: 191-198 One light chain complementarity determination region (LC-CDR)1 containing an amino acid sequence selected from the group, One LC-CDR2 containing LGSNRAS (SEQ ID NO: 51), and SEQ Amino acids selected from the group consisting of ID NO: 62 and SEQ ID NO: 69 A single LC-CDR3 containing the sequence specifically binds to Pseudomonas species Psl. Provides isolated antibodies or antigen-binding fragments.

[0023] In one aspect of the present invention, (i)V H and V L Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:1 and amino acid sequence SEQ ID NO:1 One HC-CDR2 containing 3 and one containing amino acid sequence SEQ ID NO:24 Modified HC-CDR3 containing or containing at most 5 amino acid substitutions in HC-CDRs Including a different body, the V L This is one LC-C containing amino acid sequence SEQ ID NO:37 DR1, one LC-CDR2 containing amino acid sequence SEQ ID NO:51, and It contains one LC-CDR3 containing the noacid sequence SEQ ID NO:62, or LC- The CDRs include mutants containing at most 5 amino acid substitutions, (ii)V H and V L of Including the aforementioned V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:1 and , one HC-CDR2 containing amino acid sequence SEQ ID NO:163, and amino acid Includes one HC-CDR3 containing column SEQ ID NO:36, or HC-CDR The mutant includes at most 5 amino acid substitutions in s, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:50, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 It contains LC-CDR3 or LC-CDRs containing at most 5 amino acid substitutions. (iii)V H and V L Including the above V H This is the amino acid sequence SEQ I One HC-CDR1 containing D NO:1 and amino acid sequence SEQ ID NO:163 One HC-CDR2 containing and one amino acid sequence SEQ ID NO:182 Modified HC-CDR3 containing or containing at most 5 amino acid substitutions in HC-CDRs Including a different body, the V L This is one LC-C containing amino acid sequence SEQ ID NO:37 DR1, one LC-CDR2 containing amino acid sequence SEQ ID NO:51, and It contains one LC-CDR3 containing the noacid sequence SEQ ID NO:62, or LC- The CDRs contain mutants with at most 5 amino acid substitutions, or (iv)V H Oh bi V L Including the above V H This is one HC-C containing amino acid sequence SEQ ID NO:1 DR1, one HC-CDR2 containing amino acid sequence SEQ ID NO:13, and ami It contains one HC-CDR3 containing the noacid sequence SEQ ID NO:183, or HC -CDRs include mutants containing at most 5 amino acid substitutions, and the V L is an amino acid blend One LC-CDR1 containing column SEQ ID NO:50, and amino acid sequence SEQ ID One LC-CDR2 containing NO:51 and amino acid sequence SEQ ID NO:62 It contains one LC-CDR3 and, or LC-CDRs, at most five amino acids. Isolated antibodies that specifically bind to Pseudomonas Psl, including mutants containing the compound. It provides an antigen-binding fragment.

[0024] In one aspect of the present invention, (i)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:79, or amino acid sequence SEQ ID NO:79 and at least 90% (For example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) or includes a variant sequence having sequence identity of 99%, and the V L This is the amino acid sequence SE Q ID NO:91, or amino acid sequence SEQ ID NO:91 and at least 90 % (for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) (ii)V H and V L Includes M, the aforementioned V H SEQ ID NOs:128-139, SEQ ID NOs:14 9-151 and one of the following amino acids: SEQ ID NOs: 154-155 Columns, or SEQ ID NOs:128-139, SEQ ID NOs:149-1 51, and one of the amino acid sequences of SEQ ID NOs: 154-155 and a small At least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%) The variant sequence has 97%, 98%, or 99% sequence identity, and the V L is, The amino acid sequence SEQ ID NO:91, or the amino acid sequence SEQ ID NO:91 and At least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%) (iii)V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:151, or A Mino acid sequence SEQ ID NO:151 and at least 90% (for example, at least 91%) Sequence identity of 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% The variant sequence includes having the V L The SEQ ID NOs: 140-148 Any one amino acid sequence, or any one of SEQ ID NOs: 140-148 The amino acid sequence and at least 90% (e.g., at least 91%, 92%, 93%, 94%) Includes mutant sequences with sequence identity of 95%, 96%, 97%, 98%, or 99%. (iv)V H and V L Including the above V H This is SEQ ID NO:132, SEQ ID NO:149, SEQ ID NOs:152-153, and SEQ ID NOs: Any one amino acid sequence from 156-157, or SEQ ID NO: 1 32, SEQ ID NO:149, SEQ ID NOs:152-153, and S EQ ID NOs: One amino acid sequence from 156-157 and at least 90% (For example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%) or includes a variant sequence having sequence identity of 99%, and the V L This is the amino acid sequence SE Q ID NO:143, or amino acid sequence SEQ ID NO:143 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%) Contains a variant sequence with 98% or 99% sequence identity, or (v)V Hand V L Including the above V H This is the amino acid sequence SEQ ID NO:151, or the amino acid sequence Column SEQ ID NO:151 and at least 90% (e.g., at least 91%, 92%) It has sequence identity of 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The variant sequence is included, and the V L This is the amino acid sequence SEQ ID NO:98, or amino Acid sequence SEQ ID NO: 98 and at least 90% (e.g., at least 91%, 92%) It has sequence identity of 93%, 94%, 95%, 96%, 97%, 98%, or 99%. An isolated antibody containing a mutant sequence that specifically binds to Pseudomonas Psl or It provides antigen-binding fragments.

[0025] In some examples, the antibody that specifically binds to the Pseudomonas genus Psl is used. Alternatively, competing with one of the antigen-binding fragments, Pseudomonas species Psl and specific Provides isolated antibodies or antigen-binding fragments that bind heterologously. In the example, an antibody or antigen conjugate that specifically binds to the aforementioned Pseudomonas genus Psl is used. Pseudomonas species that specifically bind to the same epitope as one of the sex fragments. This invention provides isolated antibodies or antigen-binding fragments that specifically bind to Psl.

[0026] In several examples, isolation that specifically binds to the Pseudomonas genus Psl as described above. Either the antibody or the antigen-binding fragment contains an Fc fragment. In several examples, isolated antibodies that specifically bind to Pseudomonas (Psl) were used. Alternatively, the antigen-binding fragment is a full-length IgG antibody. In some examples, , isolated antibodies or antigen-binding fragments that specifically bind to Pseudomonas Psl The antibody is a full-length IgG1 or IgG4 antibody. In some examples, the shoe Isolated antibodies or antigen-binding fragments that specifically bind to Domonas Psl are These are chimeric antibodies, human antibodies, or humanized antibodies. In some examples, pseudomod Isolated antibodies or antigen-binding fragments that specifically bind to the genus Solanum (Psl) are Fa b, Fab', F(ab)'2, Fab'-SH, single-chain antibody (scFv), Fv flag Selected from the group consisting of ment, dAb, Fd, and diabody. It is an antigen-binding fragment.

[0027] In some examples, the antibody that specifically binds to the Pseudomonas genus Psl is used. Provides an isolated nucleic acid molecule encoding either one of the following antigen-binding fragments. In some examples, a vector containing any one of the nucleic acid molecules described above is used. Provided. In several examples, it specifically binds to the aforementioned Pseudomonas genus Psl. Either one isolated antibody or antigen-binding fragment, or one nucleic acid molecule. A host cell containing either one or one of the vectors is provided. In some examples... a) an antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl. Culturing one of the aforementioned host cells under conditions that effectively express the signal, and b )Antibodies or antigens that specifically bind to Pseudomonas genus Psl expressed from host cells. Isolation of Pseudomonas genus Psl, including obtaining binding fragments. This invention provides a method for preparing antibodies or antigen-binding fragments.

[0028] In several examples, an effective amount specifically binds to the aforementioned Pseudomonas species Psl. Antibodies or antigen-binding fragments, or the aforementioned Pseudomonas genus Psl specific Administering a pharmaceutical composition containing an antibody or antigen-binding fragment that binds to a target to an individual. The invention provides a method for treating a disease or condition in an individual that requires treatment, including several. In the examples, the above-mentioned pseudomona in the manufacture of a pharmaceutical product for treating a disease or symptom Either an antibody or antigen-binding fragment that specifically binds to Psl of the genus Psl, This refers to an antibody or antigen-binding fragment that specifically binds to the aforementioned Pseudomonas species Psl. The present invention provides the use of a pharmaceutical composition containing one of the following: Alternatively, the disease is a pathogenic bacterial infection. In some cases, the infection is a Gram-negative bacterial infection. It is a stain. In some examples, the pathogen is Pseudomonas aeruginosa. In some examples The disease or condition includes one or more symptoms caused by a Pseudomonas aeruginosa infection. In the examples, the symptoms included fever, chills, fatigue, muscle and joint pain, joint swelling, and headache. Pain, diarrhea, skin rash, pus in wounds, bacteremia, acute pneumonia, and one type of intra-abdominal infection. This includes multiple species.

[0029] In some embodiments, this further includes administering one or more therapeutic agents. The present invention provides one of the aforementioned treatment methods. In some embodiments, a small amount of therapeutic agent is used. Both are antibiotics. In some examples, the antibiotic is imipenem, Bramycin, ciprofloxacin, meropenem, and one of the aztreonam There are multiple species.

[0030] In some examples, the antibody that specifically binds to the Pseudomonas genus Psl is used. Or one of the following: antigen-binding fragment, nucleic acid, vector, or isolated host cell The present invention provides pharmaceutical compositions, kits, and products. [Brief explanation of the drawing]

[0031] [Figure 1A] Figures 1A-1B show the ability of anti-Psl antibodies to inhibit the attachment of Pseudomonas aeruginosa to A549 cells, compared to the reference antibodies Wapr-001 or Cam-003. [Figure 1B] Figures 1A-1B show the ability of anti-Psl antibodies to inhibit the attachment of Pseudomonas aeruginosa to A549 cells, compared to the reference antibodies Wapr-001 or Cam-003. [Figure 1C] Figures 1C-1D show the ability of anti-Psl antibodies to promote OPK in Pseudomonas aeruginosa compared to the reference antibodies Wapr-001 or Cam-003. [Figure 1D] Figures 1C-1D show the ability of anti-Psl antibodies to promote OPK in Pseudomonas aeruginosa compared to the reference antibodies Wapr-001 or Cam-003. [Figure 2A] Figure 2A shows the ability of anti-Psl antibodies P59, 7H9, 3F12, 2A2, and 6G7 to block the attachment of Pseudomonas aeruginosa strain O1-52 / 66 to A549 cells. [Figure 2B] Figure 2B shows the ability of anti-Psl antibodies P59, 7H9, 3F12, 2A2, and 6G7 to block the attachment of Pseudomonas aeruginosa strain O6-57 / 66 to A549 cells. [Figure 2C] Figure 2C shows the ability of anti-Psl antibodies P59, 7H9, 3F12, 2A2, and 6G7 to block the attachment of Pseudomonas aeruginosa strain O16-177 / 81 to A549 cells. [Figure 2D]Figure 2D shows the ability of anti-Psl antibodies P59, 7H9, 3F12, 2A2, and 6G7 to block the attachment of Pseudomonas aeruginosa strain O2-53 / 66 to A549 cells. [Figure 3A] Figure 3A shows the ability of anti-Psl antibodies P59, 7H9, and 3F12 to promote OPK in various strains of O6-57 / 66 compared to the reference antibody psl0096. [Figure 3B] Figure 3B shows the ability of anti-Psl antibodies P59, 7H9, and 3F12 to promote OPK in various strains of O16-177 / 81 compared to the reference antibody psl0096. [Figure 3C] Figure 3C shows the ability of anti-Psl antibodies P59, 7H9, and 3F12 to promote OPK in various strains of O1-52 / 66 compared to the reference antibody psl0096. [Figure 3D] Figure 3D shows the ability of anti-Psl antibodies P59, 7H9, and 3F12 to promote OPK in various strains of O2-53 / 66 compared to the reference antibody psl0096. [Figure 4A] Figure 4A shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to block the attachment of Pseudomonas aeruginosa strain O1-52 / 66 to A549 cells. [Figure 4B] Figure 4B shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to block the attachment of Pseudomonas aeruginosa strain O2-53 / 66 to A549 cells. [Figure 4C] Figure 4C shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to block the attachment of Pseudomonas aeruginosa strain O6-57 / 66 to A549 cells. [Figure 4D] Figure 4D shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to block the attachment of Pseudomonas aeruginosa strain O16-177 / 81 to A549 cells. [Figure 5A] Figure 5A shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to promote OPK in various strains of O1-52 / 66 compared to the reference antibody psl0096. [Figure 5B]Figure 5B shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to promote OPK in various strains of O16-177 / 81 compared to the reference antibody psl0096. [Figure 5C] Figure 5C shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to promote OPK in various strains of O6-57 / 66, compared to the reference antibody psl0096. [Figure 5D] Figure 5D shows the ability of anti-Psl antibody mutants P59-m21 or 7H9-m23 to promote OPK in various strains or O2-53 / 66 compared to the reference antibody psl0096. [Figure 6A] Figure 6A shows the binding specificity of anti-Psl antibodies 3F12, 7H9-m23, and P59-m21 against the WFPA800 strain, as measured by ELISA. [Figure 6B] Figure 6B shows the binding specificity of anti-Psl antibodies 3F12, 7H9-m23, and P59-m21 against the WFPA801 strain, as measured by ELISA. [Figure 7] Figure 7 shows the cross-reactivity of anti-Psl antibodies 3F12, 7H9-m23, and P59-m21 against BV particles compared to the reference antibody psl0096. [Figure 8] Figure 8 shows the ability of different doses of anti-Psl antibodies 3F12, 7H9-m23, or P59-m21 to inhibit Pseudomonas aeruginosa biofilm formation compared to the reference antibody psl0096. [Figure 9A] Figure 9A shows that, compared to the reference antibody Cam-003, the anti-Psl antibody P59 at a dose of 15 mg / kg mouse body weight has the ability to enhance survival in a mouse bacteremia model inoculated with twice the lethal dose (2 × LD90) of Pseudomonas aeruginosa (57 / 66). [Figure 9B] Figure 9B shows that, compared to the reference antibody Cam-003, anti-Psl antibodies P59, 1D10, 7H9, 2A2, or 6G7, at a dose of 10 mg / kg mouse body weight, enhance survival in a mouse bacteremia model inoculated with Pseudomonas aeruginosa (57 / 66) at three times the lethal dose (3 × LD90). [Figure 9C] Figure 9C shows that, compared to the reference antibody psl0096, anti-Psl antibodies 3F12 or 7H9, at a dose of 10 mg / kg mouse body weight, enhance survival in a mouse bacteremia model inoculated with Pseudomonas aeruginosa (57 / 66) at four times the lethal dose (4 × LD90). [Figure 9D] Figure 9D shows that in a mouse bacteremia model inoculated with Pseudomonas aeruginosa (57 / 66) at four times the lethal dose (4 × LD90), anti-Psl antibody mutants 7H9-m23, 7H9-m24, 7H9-m25, 3F12-m01, or P59-m21 at a dose of 10 mg / kg mouse body weight have the ability to enhance survival rates. [Figure 10] Figure 10 shows the ability of anti-Psl antibody mutants 3F12-m01, 7H9-m24, or P59-m21 to reduce the bacterial load in the lungs, spleen, and kidneys. [Figure 11] Figure 11 shows the ability of anti-Psl antibody 3F12, administered alone or in combination with the antibiotics meropenem (MEM), tobramycin (TOB), or ciprofloxacin (CIP), to enhance survival rates in an intraperitoneal infection model inoculated with three times the lethal dose (3 × LD90) of Pseudomonas aeruginosa (57 / 66). [Figure 12] Figure 12 shows the pharmacokinetic profiles of anti-Psl antibodies 3F12, 7H9-m23, P59-m21, and the reference antibody psl0096 in rats when administered intravenously at a dose of 3 mg / kg. [Modes for carrying out the invention]

[0032] In one aspect of the present invention, an antibody or antigen conjugate that specifically binds to Pseudomonas (Psl) is present. Provides sex fragments. Screening and affinity analysis of scFv phage libraries. By using a combination of maturity and properly designed biochemical and biological assays Therefore, a highly effective antibody molecule that specifically binds to Psl was identified. The antibody in question is A54. It inhibits the attachment of Pseudomonas aeruginosa to cells, promotes the OPK of Pseudomonas aeruginosa, and, in It can provide both therapeutic and prophylactic protection against Pseudomonas aeruginosa in vivo.

[0033] The antibody or antigen provided by the present invention that specifically binds to Pseudomonas Psl. Binding fragments include, for example, full-length anti-Psl antibodies and anti-Psl single-chain antibodies (scFvs). ), anti-Psl Fc fusion protein, multispecific (e.g., bispecific) anti-Psl antibody, anti Includes PSL immune complexes, etc.

[0034] In several examples, it specifically binds to Pseudomonas Psl and a specific sequence The antibodies or antigen-binding fragments that possess these antibody or antigen-binding flags Competing with the ment, or the same epiton as these antibody or antigen-binding fragments Provides an antibody that binds to p.

[0035] The present invention also relates to antibodies or antigen-binding agents that specifically bind to Pseudomonas Psl. A composition comprising nucleic acid encoding a lagment, an anti-Psl antibody, and a method for preparing the anti-Psl antibody. It provides a method for calling and using it.

[0036] definition As described herein, “treatment” or “treating” "Treatment" is a method of obtaining results that include favorable or desired clinical outcomes. In view of the object of the present invention, the above advantageous or desired clinical results are due to one or more diseases. To alleviate several symptoms, reduce the severity of the disease, and stabilize the disease (for example, To prevent or delay the worsening of a disease, or to prevent or delay the spread of a disease (e.g., pathogens) (systemic diffusion of the virus), preventing or delaying disease recurrence, slowing or delaying disease progression. To improve the condition of a disease, to alleviate a disease (in part or in whole), to treat a disease Reducing the amount of one or more other drugs needed for the condition, and slowing the progression of the disease. , improving or increasing survival mass, increasing body weight, and / or survival period This includes, but is not limited to, one or more selected from the group consisting of "extension". No. At the same time, "treatment" also reduces the pathological consequences of the infection (e.g., the lysis of host cells). This includes (dissolution or necrosis). The methods of the present invention consider one or more of these treatments. do.

[0037] The terms "prevent" and "prevented" "preventing", "prevention" What similar words describe the onset or recurrence of a disease or illness (e.g., infection by a pathogen)? It shows ways to prevent, inhibit, or reduce the possibility of a certain disease or condition. To delay the onset or recurrence of symptoms of a certain disease or condition. It refers to delay. As used here, "prevention" and Similar words refer to the intensity, effects, symptoms, and / or the onset or recurrence of a disease or illness. or further include reducing the burden. As used here, "prevention (preve "Ntion" and similar words refer to a disease or illness, such as the outbreak of an infection caused by a pathogen or This further includes reducing the risk and susceptibility to recurrence.

[0038] The term "antibody" includes full-length antibodies and their antigen-binding fragments. The antibody contains two heavy chains and two light chains. The variable regions of the heavy chain and light chain interact with the antigen. It is responsible for the linkage. The variable region in the two chains generally contains three highly variable loops. The loop is called a complementarity-determining region (CDR) (light chain (LC) CDRs are LC- It includes CDR1, LC-CDR2 and LC-CDR3, and heavy chain (HC)CDRs are H (Includes C-CDR1, HC-CDR2, and HC-CDR3.) The antibodies described in this invention Alternatively, the CDR boundary of the antigen-binding fragment is Kabat, Chothia, or Al- Defined or recognized by the conventions of Lazikani (Al-Lazikani 199) 7; Chothia 1985; Chothia 1987; Chothia 19 89; Kabat 1987; Kabat 1991). Three Cs of the heavy or light chain. The DR region is inserted between the flanking regions, which are called framework regions (FRs). The aforementioned framework regions (FRs) have even higher preservation capabilities than the CDR region, and are highly It forms a support structure that supports the variable loop. The constant regions of the heavy chain and the light chain bind to the antigen. Although they do not participate in synthesis, they exhibit various effects and functions. Antibodies are the amino acids in the constant region of their heavy chains. They are classified based on their sequence. The five main classes or isotypes of antibodies are IgA, I gD, IgE, IgG, and IgM, and IgA, IgD, IgE, IgG, and Ig M is characterized by having α, δ, ε, γ, and μ-type heavy chains, respectively. Classes are subclasses, for example, IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG 3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain n) or IgA2 (α2 It is classified as a heavy chain.

[0039] As described herein, the term “antigen-binding fragment” means, for example, diabody, Fab, Fab', F(ab')2, Fv fragment Disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific ds Fv(dsFv-dsFv'), disulfide-stabilized diabody (ds diabody) , single-chain antibody (scFv), scFv dimer (bivalent diabody), one or more CDRs Multispecific antibodies, single-domain antibodies, nanobodies, and other antibodies consisting of antibody fragments containing s. Main antibody, bivalent domain antibody, or an antibody that can bind to an antigen but does not contain a complete antibody structure. Refers to an antibody fragment containing any other antibody fragment. Antigen-binding fragment It further contains a fusion protein comprising the antibody fragment. Antigen-binding fragment The antibody can bind to the same antigen as the parent antibody or parent antibody fragment (e.g., parent scFv). In some examples, the antigen-binding fragment is one or more different human antibodies. Includes one or more CDRs from specific human antibodies transplanted into a framework region. obtain.

[0040] As described herein, the term “epitope” means an antibody or an antibody portion bound to an antibody. Refers to a specific group of atoms or amino acids on an antigen that binds. Two types of antibodies or antibody parts. If the molecules exhibit competitive binding to the antigen, they can bind to the same epitope within the antigen. ru.

[0041] As described herein, the first antibody, in the presence of an equimolar concentration of the first antibody, the second antibody Target Psl binding in the body should be at least 50% (e.g., at least 55%, 60%, 65%). Fields that inhibit 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% Regarding binding to the Psl target, it "competes" with the second antibody, or vice versa. The publication WO 03 / 48731 contains information on high-throughput antibody cross-competition. The method for classifying the body's "epitope" is described.

[0042] As described herein, “specifically bind,” “specifically recognize,” or “to….” The term "specific to" refers to measurable and reproducible interactions, e.g., biological interactions. This refers to the binding between a target and an antibody that determines the presence of the target in the presence of a heterogeneous group of molecules, including the target molecule itself. For example, the ability of an antibody to specifically recognize a target (which may be an epitope) means that The binding of this antibody to this target has a higher affinity compared to the binding of this antibody to other targets. It refers to having a higher bonding strength, being easier to bond, and having a longer duration. In the example, the antibody that specifically recognizes the antigen has low binding affinity to other targets. At the very least, it reacts with one or more antigenic determinants of the antigen with a binding affinity 10 times greater.

[0043] As described herein, “isolated” anti-Psl antibodies are (1) naturally occurring (2) It is unrelated to protein, and does not contain other proteins from the same source, (3 ) Anti-Psl antibodies expressed by cells of a different species, or (4) anti-Psl antibodies that do not exist in nature. vinegar.

[0044] As described herein, the term “isolated nucleic acid” means genome, cDNA, etc. This refers to synthetic nucleic acids, or combinations thereof. According to its origin, the aforementioned "isolated "Nucleic acid" is (1) all of the polynucleotides in "isolated nucleic acids" found in nature. (2) Polynucleotides that are unrelated to or in part to it and are not linked to it in their natural state It is operably linked to, or does not exist naturally as part of a larger sequence than (3). It refers to something.

[0045] As described herein, the terms “CDR” or “complementarity determination area” are important. This refers to discontinuous antigen-binding sites found in the variable regions of chain polypeptides and light chain polypeptides. vinegar. Kabat et al., J. Biol. Chem. 252:6609-66 16(1977); Kabat et al., US Dept. of Hea lth and Human Services,“Sequences of professional teins of immunological interest” (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J.Mol. B iol., 273: 927-948 (1997); al., J. Mol. Biol. 262:732-745 (1996); A bhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc MP et al., Dev. Comp. Immunol., 27: 55-77 (2003); approximately and Honegger and Pluckthun, J. Mol. Biol., These specific areas have already been described in 309:657-670 (2001). When comparing them to each other, these definitions include duplication or subsetting of amino acid residues. However, any definition of CDR for antibodies or transplanted antibodies or their variants This is intended to be within the scope of the terms defined and used herein. (See above references) For comparison, the amino acid residues containing CDR as defined for each of these are listed in Table 1. R prediction algorithms and interfaces are known in this field, for example, Abh inandan and Martin,Mol.Immunol.,45:3832- 3839(2008);Ehrenmann F.et al., Nucleic Ac ids Res.,38:D301-D307(2010);and Adolf-Bry fogle J. et al., Nucleic Acids Res.,43:D43 The literature, including 2-D438(2015), provides an explanation. The references cited in this paragraph are... The contents are to be used in this application and included in one or more claims of the present invention. It is incorporated into this specification as a whole so that it can be used.

[0046] [Table 1]

[0047] The term "chimeric antibody" refers to an antibody in which part of the heavy chain and / or light chain originates from a specific species. The sequence is identical to the corresponding sequence in an antibody, or an antibody belonging to a specific antibody class or subclass. These are homologous, and the rest of these chains are derived from other species or other antibody classes or This refers to an antibody that is identical or homologous to the corresponding sequence in an antibody belonging to a subclass. Such antibody fragments only need to possess the biological activity of the present invention (USP agent No.4,816,567;and Morrison et al.,P roc.Natl.Acad.Sci.USA,81:6851-6855(1984) (See reference).

[0048] "Fv" is the smallest antibody fragment that contains intact antigen recognition and binding sites. The fragment consists of one heavy chain variable domain and one light chain variable domain. It is a dimer linked by non-covalent bonds. From the folding of these two domains, six A variable altitude loop is created (three loops each for the light and heavy chains), and the altitude variable The loop provides amino acid residues for antigen binding, conferring antigen-binding specificity to the antibody. However, a single variable domain (or half containing only three antigen-specific CDRs) Even if it is an Fv fragment, its affinity is lower than that of the intact binding site. Furthermore, it possesses the ability to recognize and bind to antigens.

[0049] "Single-stranded Fv," also called "sFv" or "scFv," is a single polypeptide chain. Linked V H antibody domain and V L This refers to an antibody fragment containing an antibody domain. In several examples, the scFv polypeptide has an ideal structure for antigen binding. V H and V L Further includes linked polypeptides between. (ScFv outline) Regarding the main point, Pluckthun in The Pharmacology of M onoclonal antibodies,vol.113,Rosenburg a nd Moore eds., Springer-Verlag, New York, p. See pp. 269-315 (1994).

[0050] The term "diabodies" is a short linker (for example, 5~ V (using 10 residues) H and V L Between them is an scFv fragment (see the content of the paragraph above). This refers to a small antibody fragment prepared by constructing a variable The domain achieves inter-chain pairing rather than intra-chain pairing, resulting in a divalent fragment, i.e., two A fragment containing an antigen-binding site is generated. The bispecific diabody has two "Crossover" scFv fragment heterodimer, containing two antibodies V H Domain and V L The domain is located on a different polypeptide chain. EP 404 ,097;WO93 / 11161;Hollinger et al.,Proc.Na In tl.Acad.Sci.USA,90:6444-6448(1993), I gave a full explanation regarding the diamond body.

[0051] The "humanization" form of non-human (e.g., rodent) antibodies is the minimum amount derived from the non-human antibody. It is a chimeric antibody containing a row. Most humanized antibodies are human immunoglobulins (recipient) The antibody is an antibody, and the residues derived from the hypervariable region (HVR) of the recipient antibody are the desired antibody. A mouse, rat, rabbit, or non-human primate animal possessing specificity, affinity, and performance. It is replaced by a hypervariable region derived from a non-human species (donor antibody). In certain cases, Residues in the framework region (FR) of human immunoglobulins correspond to non-human residues. It is replaced by [this]. Note that the humanized antibody is a residue that is not present in either the recipient antibody or the donor antibody. It may also contain the group. These modifications can further improve the performance of the antibody. Humanized antibodies contain substantially at least one, typically two, variable domains within them. All or substantially all highly variable loops are all highly variable loops of non-human immunoglobulins. The framework region corresponds to the human immunoglobulin sequence. Human antibodies are, at random, selected from at least a portion of the constant region (Fc) of immunoglobulins. Typically, this includes the constant region of human immunoglobulins. For details, see Jones et al. Nature 321:522-525(1986);Riechmann et al. ., Nature 332:323-329(1988); and Presta, Cur You should refer to r.Op.Struct.Biol.2:593-596(1992). .

[0052] The amino acid sequence identity percentage (%) of polypeptides and antibody sequences identified herein. ")" or "homology" refers to comparing sequences by considering conservative substitutions as part of sequence identity. , the occupancy of the same amino acid residues in the candidate sequence and the polypeptide sequence to be compared It is defined as a percentage. The percentage of amino acid sequence identity varies within the technical scope of this field. A comparison method, for example, BLAST, BLAST-2, ALIGN, Megalign(D Available computer software such as NASTAR or MUSCLE software This can be determined by the software. Those skilled in the art can determine the most over the entire length of the compared sequences. Appropriate algorithms for measurement and comparison, including any algorithms necessary to achieve large-scale comparisons. The parameters can be determined. However, for the purpose of the present invention, amino acid composition The value of the column identity percentage is obtained from the sequence comparison computer program MUSCLE(Edgar, RC, Nucleic Acids Research 32(5):1792- 1797, 2004; Edgar, RC, BMC Bioinformat It was generated using ics 5(1):113, 2004).

[0053] The term "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. It is used to clarify. In some embodiments, the FcR described in the present invention is I It is an FcR that binds to the γ antibody (a type of γ receptor), and is also known as FcγRI, FcγRII, and It includes receptors of the FcγRIII subclass, and allelic variants and selections of these receptors. This also includes alternative splicing forms. The FcγRII receptor is an activating receptor. ) and FcγRIIB (inhibitory receptor). FcγRIIA (activating receptor) and FcγRIIB (inhibitory receptor) has a similar amino acid sequence, mainly in the cytoplasmic domain. However, there is a difference. The activating receptor FcγRIIA has an immune response in its cytoplasmic domain. It contains a tyrosine activation motif (ITAM). The inhibitory receptor FcγRIIB is its detailed The cytoplasmic domain contains an immune receptor tyrosine inhibitor motif (ITIM) (M. in Daeron (See Annu. Rev. Immunol. 15:203-234 (1997)) The aforementioned term refers to allomorphs of the same species, for example, the allomorph of FcγRIIIA: FcγRIIIA-Ph e158, FcγRIIIA-Val158, FcγRIIA-R131 and / or Further contains FcγRIIA-H131. Ravetch and Kinet, Ann u.Rev.Immunol 9:457-92(1991) and Capel et al. al., Immunomethods 4:25-34 (1994); and de Ha as et al., J.Lab.Clin.Med.126:330-41(1995 ) explained in relation to FcRs. The term FcR in this invention may be specified in the future. It contains other types of FcRs, including those found in maternal IgGs. The term FcR refers to maternal IgGs. This also includes the neonatal receptor FcRn, which is responsible for the transition to the newborn (Guyer et al., J.Immunol.117:587(1976)and Kim et al.,J. Immunol. 24:249 (1994).

[0054] The term "FcRn" refers to the neonatal Fc receptor (FcRn). FcRn is a major It is structurally similar to the histocompatibility complex (MHC), and its α chain is not co-located with β2-microglobulin. It is composed of binding. Multiple functions of the neonatal Fc receptor FcRn are Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739-766. It is explained there. FcRn is a passive transfer of immunoglobulin IgGs from mother to newborn. It plays a crucial role in transport and regulation of serum IgG levels. FcRn is rescue - As a receptor, it binds IgG that has been completely endocytized both intracellularly and between cells. Combine and transport them, rescuing them from their default disintegration routes.

[0055] The "CH1 domain" in the human IgG Fc region typically starts from amino acid 118 to 215. Extends to amino acids at the next position (EU numbering system).

[0056] The "hinge region" is typically located from position 216 (Glu) to position 230 (P) of human IgG1. ro(Burton,Molec.Immunol.22:161-206(1985) It is defined as the range that extends up to the first and last chains that form disulfide bonds between heavy chains. By positioning the stain residue at the same location as IgG1, other IgG isotypes The hinge region can be compared with the IgG1 sequence.

[0057] The "CH2 domain" in the human IgG Fc region typically starts from amino acid 231 to 340. It extends to the amino acid at the next position. The CH2 domain does not closely pair with other domains. It is unique in that respect. Instead, the branched sugar chain linked at two N-terminuses is a complete form of heaven The sugar is inserted between the two CH2 domains of the natural IgG molecule. It can be used as a compound substitution and is presumed to contribute to the stability of the CH2 domain. ton, Molec Immunol. 22:161-206 (1985).

[0058] The "CH3" domain is located within the Fc region, and the CH2 domain (at position 341) is located at the C-terminal residue. From the no acid to the C-terminus of the antibody sequence, typically the amino acid residue at position 446 or 447 of IgG. This includes the portion that extends up to ).

[0059] "Functional Fc fragments" possess the "effector function" inherent in the natural arrangement of Fc regions. It features C1q binding, complement-dependent cell-mediated cytotoxicity (CDC). An example of an "effector function" is C1q binding, complement-dependent cell-mediated cytotoxicity (CDC). ), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, cell surface receptor This includes downregulation (e.g., B cell receptor; BCR). Regarding the function of the receptor, typically, the Fc region and the binding domain (e.g., the antibody variable domain) This requires a combination of methods and can be evaluated using various experimental methods known in this field. .

[0060] Antibodies of IgG Fc variants with altered FcR binding affinity or ADCC activity Compared to the parent polypeptide or a polypeptide containing a natural Fc sequence, its FcR Binding activity and / or ADCC activity are increased or decreased. "Binding to FcR is Fc variants exhibiting "enhancement" are polypropylenes containing the parent polypeptide or the native IgG Fc sequence. Peptides have a higher affinity for at least one type of FcR (for example, a lower affinity...) It has a Kd or IC50 value. In some examples, the binding ability is the parent polymer Compared to peptides, it increases by approximately three times, for example, 5, 10, 25, 50, 60, 100, 150 It can increase the bonding ability by up to 200 times, 500 times, or improve the bonding ability by 25% to 1000%. Fc variants that show "reduced binding" to FcR are at least more effective than the parent polypeptide. Lower affinity for a certain type of FcR (e.g., higher apparent Kd or IC50 value) ) has a binding ability that is 40% or more lower than that of the parent polypeptide.

[0061] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" is a form of cytotoxicity, and secretion is involved. The Ig that is released is used in certain cytotoxic cells (e.g., natural killer cells (NK), neutrophils and It binds to Fc receptors (FcRs) present in macrophages, and these cytotoxic effects The cultor cells are specifically bound to target cells that carry antigens, and then cytotoxins are used to target them. It refers to killing cells. Antibodies "arm" cytotoxic cells because their toxicity is necessary. In the main cell types mediated by ADCC, NK cells express only FcγRIII. Mononuclear cells express FcγRI, FcγRII, and FcγRIII. and Kinet, Annu. Rev. Immunol 9:457-92( Table 3 on page 464 of the 1991 edition summarizes FcR expression in hematopoietic cells. To evaluate the ADCC activity of the target molecule, an in vitro ADCC experiment will be performed. This is possible, and this is described in U.S. Patent No. 5,500,362 or 5,821,337. It is explained that suitable effector cells for such experiments include peripheral blood mononuclear cells (PB). Includes MCs and natural killer (NK) cells. Selectively, ADCs of the target molecule. C activity can also be evaluated in vivo, for example, Clynes et al. PNAS This is explained in the animal model disclosed in (USA)95:652-656(1998). It is.

[0062] A polypeptide containing wild-type IgG Fc or a parent polypeptide containing a mutant Fc region The polypeptide exhibits "enhanced ADCC activity" in the presence of human effector cells. However, the polypeptide containing the mutated Fc region can more effectively intervene in the ADCC effect, During the experiment, the amount of polypeptide containing wild-type IgG Fc (or parent polypeptide) was substantially If they are essentially the same, ADCC is used in either in vitro or in vitro situations. It can intervene more effectively. Typically, such variants are any in-vitro known in this field. ADCC is identified using the ADCC experimental method described above, for example, by identifying ADCC activity in animal models. These are used in experiments and methods that utilize the like. In some examples, such mutants are Compared to wild-type Fc (or parent polypeptide), the effect mediated by ADCC is 5- It improves by 100 times, for example, 25 to 50 times.

[0063] "Complement-dependent cell injury" or "CDC" refers to the lysis of target cells in the presence of complement. This refers to the activation of a typical complement pathway, which involves the first component of the complement system (C1q) and homologous receptors. Complement is initiated by binding to an antibody (a subclass with the appropriate structure) that binds to the progenitor. To evaluate activation, for example, Gazzano-Santoro et al., C, as explained in J. Immunol. Methods 202:163 (1996) DC experiments may be conducted. U.S. Patent No. 6,194,551B1 and WO99 / 51 In 642, the amino acid sequence of the Fc region was altered, and the C1q region was increased or decreased. Polypeptide variants with binding ability are described. The contents of these patent publications are cited. As used, it is explicitly incorporated herein. Also, Idusogie et al. J See Immunol. 164: 4178-4184 (2000).

[0064] Unless otherwise specified, "nucleotide sequences that encode amino acid sequences" are degenerate. and include all nucleotide sequences that encode the same amino acid sequence. The nucleotide sequence encoding RNA may further contain introns, for example, Protein-coding nucleotide sequences contain introns in several forms. .

[0065] The term "operably linked" refers to the functional linking between a regulatory sequence and a heterologous nucleotide sequence. This refers to the connection, which in turn causes the latter to be expressed. For example, the first nucleotide sequence and the second nucleotide sequence If the cleotide sequences have a functional relationship, then the first nucleotide sequence and the second nucleotide... The coding sequence is operably linked. For example, a promoter can suspend the transcription or expression of the coding sequence. If it has an effect, the promoter and the code sequence are linked in an operable manner. Normally, The DNA sequences that can be linked are continuous, and, if necessary, two protein-coding regions. The domains can be linked within the same open reading frame.

[0066] "Homologousness" refers to the similarity between two polypeptides or two nucleic acid components. This refers to sequence similarity or sequence identity between offspring. The same position in the two sequences being compared is the same base. Or, if it is an amino acid monomer subunit, for example, at the same position in two DNA molecules If both are adenine, then the two DNA molecules are homologous at that position. The percentage of homology between two sequences is the percentage of shared coincidences relative to the total number of positions. This is a function that multiplies the ratio of the number of homologous positions by 100. For example, in two arrays, 10 If six of the positions are identical or homologous, the two sequences have 60% homology. For example, the homology between the DNA sequences ATTGCC and TATTGC is 50%. Typically, two pairs When comparing columns, the comparison is performed to obtain the greatest degree of homology.

[0067] The “effective amount” of the anti-Psl antibody or composition described herein refers to the amount required to achieve a specific purpose. This refers to a sufficient amount. "Effective amount" is determined by experience and known methods related to the aforementioned purpose. It can be decided by doing so.

[0068] The term "therapeutic effective dose" means that the amount of the anti-Psl antibody or composition described herein is sufficient for an individual to... This refers to the amount of use that can effectively "treat" a disease or disorder. In the case of Pseudomonas aeruginosa infection, this specification refers to The therapeutically effective dose of the described anti-Psl antibody or composition reduces the number of infected cells and the spread of infection. It inhibits (i.e., mitigates or preferably stops to some extent) and / or infection-related This is an amount that can alleviate one or more symptoms. If infected, see below. Anti-Psl antibodies or compositions inhibit the growth of Pseudomonas aeruginosa and / or kill Pseudomonas aeruginosa. Anti-Psl antibodies can be cell proliferation inhibitory or cytotoxic. In some cases, the therapeutically effective dose refers to the amount that inhibits infection in the patient. In some cases, the therapeutically effective dose refers to the amount that completely eradicates the infection in the patient. .

[0069] As used herein, “pharmaceutically acceptable” or “pharmacologically compatible” "A material that is not biologically active or does not possess other undesirable properties" is an example. For example, the material is formulated in such a way that it does not cause undesirable biological effects or harmful effects. To prevent interaction with any other components contained in the pharmaceutical composition administered to the patient, it is not added to the pharmaceutical composition administered to the patient. It is possible. A pharmaceutically acceptable carrier or excipient is preferably toxicological or It must meet the standards required for manufacturing testing and / or be edited by the U.S. Food and Drug Administration. It is included in the active ingredient guide.

[0070] The embodiments of this application described herein consist of "...consisting of..." and / or "substantially..." It should be understood that this includes examples of "consisting of...".

[0071] The term "about" as used herein refers to a numerical value or parameter, and such numerical value or parameter This includes (and explains) variants of the term itself. For example, the explanation of "about X" is given by "X". Includes an explanation of the counter-argument.

[0072] As used herein, a number or parameter does not have a corresponding "not" The explanation usually means "other than" the numerical value or parameter in question. Let me explain. For example, the statement that this method cannot be used to treat type X infection means that this method is not suitable for treating type X infection. This usually means it is used to treat types of infection other than type X.

[0073] Unless otherwise explicitly stated, the singular form "1" as used herein and in the claims, "One" and "the relevant" include multiple objects.

[0074] Anti-Psl antibody One aspect of the present invention provides an anti-Psl antibody that specifically binds to Psl. The antibodies include humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and the heavier antibodies described herein. This includes, but is not limited to, antibody molecules containing chain CDRs and / or light chain CDRs. One aspect of the present invention provides an isolated antibody that binds to Psl. The body, for example, full-length anti-Psl antibodies (e.g., full-length IgG1, IgG2, or IgG4) ), anti-Psl single-chain antibodies, multispecific (e.g., bispecific) anti-Psl antibodies, anti-Psl antibodies This includes disease complexes, etc. In some examples, the anti-Psl antibody is Fab, Fab', F(ab)'2, Fab'-SH, single-chain antibody (scFv), Fv fragment, dAb These are Fd, nanobody, diabody, or linear antibodies. In the example, the antibody that specifically binds to Psl is defined as having an antibody binding affinity to Psl. , at least 10 times greater than the binding affinity of the antibody to the non-target (e.g., 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 This refers to being (times). In some examples... In this context, "non-target" refers to antigens that are not Psl. Binding affinity is, for example, in ELISA. Fluorescence-activated cell sorting (FACS) analysis, or radioactive immunoprecipitation (RIA) analysis It can be measured by any known method in this field. The Kd value is, for example, a surface plasma Known technologies in this field, such as Mon resonance (SPR) or biolayer interference (BLI) It can be measured by various methods.

[0075] In some examples, antibodies that specifically bind to the Pseudomonas genus Psl, The antigen-binding fragment (a) promotes opsonin phagocytosis (OPK) of Pseudomonas aeruginosa, (b) To reside in or enhance the presence of Pseudomonas aeruginosa, and / or to inhibit the attachment of Pseudomonas aeruginosa to epithelial cells.

[0076] This specification refers to anti-Psl antibodies containing human sequences (e.g., human heavy chains containing human CDR sequences). The text provides a detailed explanation of the variable domain and the light chain variable domain, but also discusses non-human antibodies. Psl antibodies have also been considered. In some examples, non-human anti-Psl antibodies have been used. The document includes the human CDR sequence and non-human framework region sequence of the anti-Psl antibody described in the details. In some embodiments, the non-human framework region sequence is, for example, mouse, rat Rabbits, pigs, cattle (e.g., cows, oxen, water buffalo), deer, sheep, goats, Mammalian animals such as chickens, cats, dogs, ferrets, and primates (e.g., baby monkeys, macaques) Using one or more human CDR sequences described herein, including the substance, to create a heavy chain variable domain and Contains any sequence that may be used to form a variable light chain domain. In the examples, the non-human anti-Psl antibody is one or more human CDR sequences as described herein. non-human framework regions (e.g., mouse or chicken framework region arrays) It contains anti-Psl antibodies produced by transplantation into ).

[0077] In some examples, the anti-Psl antibodies described herein are used in relation to Pseudomonas species Ps It specifically recognizes one epitope of l. In some embodiments, the anti-Psl anti The body is specific to the Pseudomonas genus Psl and does not cross-react with other types of proteins. stomach.

[0078] In some examples, the anti-Psl antibody has a constant region in the antibody heavy chain and a constant region in the antibody light chain. Includes the constant region. In some examples, the anti-Psl antibody is the IgG1 heavy chain constant region. The region includes. In some examples, the anti-Psl antibody has a constant region of the IgG2 heavy chain. Includes. In some examples, the anti-Psl antibody includes the IgG3 heavy chain constant region. In some examples, the anti-Psl antibody includes the IgG4 heavy chain constant region. In some embodiments, IgG refers to human IgG. The heavy chain constant region includes the amino acid sequence SEQ ID NO:160, or It consists of an amino acid sequence SEQ ID NO:160. In some examples, the weight The chain constant region contains the amino acid sequence SEQ ID NO:161, or the amino acid sequence The column consists of SEQ ID NO:161. In some examples, the anti-Psl antibody It includes the λ light chain constant region. In some examples, the anti-Psl antibody has a κ light chain constant region. It includes a constant region. In some examples, the constant region of the light chain is the amino acid sequence SEQ Includes ID NO:162 or derived from the amino acid sequence SEQ ID NO:162 In some examples, the anti-Psl antibody has an antibody heavy chain variable domain and an antibody Includes light chain variable domains.

[0079] In one aspect of the present invention, the heavy chain variable domain (V H ) including the V H is SEQ ID NOs: Containing one amino acid sequence or variant thereof from 2-3 and 5-12 The aforementioned mutants contain at most three (e.g., one, two, or three) amino acid substitutions. One heavy chain complementarity determination region (HC-CDR) 1 and SEQ ID NOs: 14-15 , and one amino acid sequence or variant thereof of 17-23, the variant A single HC contains at most three amino acid substitutions (e.g., one, two, or three). -CDR2 and one of the following SEQ ID NOs: 25-26 and 28-34 The sequence includes an amino acid sequence or its variants, and the variants include at most three (for example, 1, 2 or Isolated anti-P22011, containing one HC-CDR3 with three amino acid substitutions. We provide SL antibodies.

[0080] In one aspect of the present invention, the anti-Psl antibody has a light chain variable domain (V L ) including the V L This is one amino acid from SEQ ID NOs: 38-39 and 41-49. The sequence or its variants, and the variants include at most three (e.g., one, two, or three) One light chain complementarity-determining region (LC-CDR)1 containing amino acid substitutions, and SEQ ID NOs: One amino acid sequence from 52-53 and 55-61 or The mutant includes at most three (e.g., one, two, or three) amino acid substitutions. One LC-CDR2 containing, SEQ ID NOs: 63-64, 66- The amino acid sequence comprises one of 68 and 70-75 or a variant thereof, and the variant A single variant that contains at most three amino acid substitutions (e.g., one, two, or three) Includes LC-CDR3.

[0081] In one aspect of the present invention, the anti-Psl antibody is V H and V L Including the above V H SE Q ID NOs: One amino acid sequence or variant of 2-3 and 5-12 It includes variants, and the aforementioned variants contain at most three (e.g., one, two, or three) amino acid substitutions. One HC-CDR1, and SEQ ID NOs: 14-15, and 17 -23 comprises any one amino acid sequence or a variant thereof, and the variants are at most 3 One HC-CDR2 containing (e.g., 1, 2, or 3) amino acid substitutions and , SEQ ID NOs: one of the amino acid sequences 25-26 and 28-34 or a variant thereof, wherein the variant has at most three (e.g., one, two, or three) ami The V L is SEQ ID NOs: Any one amino acid sequence or variant of 38-39 and 41-49 The variant includes at most three (e.g., one, two, or three) amino acid substitutions. One LC-CDR1, and SEQ ID NOs: 52-53, and 55-6 It contains any one amino acid sequence or a variant thereof, and the variants include at most three ( For example, one LC-CDR2 containing one, two, or three amino acid substitutions, and S EQ ID NOs: One of the following meshes: 63-64, 66-68, and 70-75 It contains a no-acid sequence or its variants, and there are at most three such variants (for example, one, two, or three). It contains one LC-CDR3 which has the amino acid substitution of ).

[0082] In some embodiments, the amino acid substitutions are as shown in Table 8 of the present invention as "exemplary". The term is limited to "substitution." In some examples, amino acid substitutions are as shown in Table 8 of the present invention. It is limited to "preferred substitutions".

[0083] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , containing one of the amino acid sequences with SEQ ID NOs: 2-3 and 5-12 HC-CDR1 and one of the following SEQ ID NOs: 14-15 and 17-23 HC-CDR2 containing two amino acid sequences, SEQ ID NOs:25-26, and The V L teeth, SEQ ID NOs: Choose one amino acid sequence from either 38-39 or 41-49. Includes LC-CDR1 and any of SEQ ID NOs: 52-53 and 55-61 LC-CDR2 containing one amino acid sequence, and SEQ ID NOs: 63-64, 6 Contains LC-CDR3 containing one of the amino acid sequences 6-68 and 70-75. nothing.

[0084] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth SEQ ID NOs: One of the following meshes: 80-81, 83-90, and 159 V having an ano acid sequence H HC-CDR1, HC-CDR2 and HC-CDR3 in Including the aforementioned V L This refers to SEQ ID NOs: 92-93, 95-97, and 99-10 V having one of the amino acid sequences of 4 L LC-CDR1, LC-CDR2 and includes LC-CDR3.

[0085] In some examples, the anti-Psl antibody is (i)V H Including the above V H is, One HC-CDR1 containing amino acid sequence SEQ ID NO:2 and amino acid sequence SEQ One HC-CDR2 containing ID NO:14, and amino acid sequence SEQ ID NO: It contains one HC-CDR3 containing 25, or at most 5 meshes in HC-CDRs. (ii)V H Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:3 and amino acid sequence SEQ ID NO:15 One HC-CDR2 containing and one H containing amino acid sequence SEQ ID NO:26 Mutations containing C-CDR3 or HC-CDRs containing at least 5 amino acid substitutions Including the body, (iii)V H Including the above V H The amino acid sequence SEQ ID NO:5 It contains one HC-CDR1 and one HC containing amino acid sequence SEQ ID NO:17 -CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:28 Contains, or contains mutants with at most 5 amino acid substitutions in HC-CDRs, (iv )V H Including the above V H This is one HC-C containing amino acid sequence SEQ ID NO:6 DR1, one HC-CDR2 containing amino acid sequence SEQ ID NO:18, and ami It contains one HC-CDR3 containing the noacid sequence SEQ ID NO:29, or HC- The CDRs contain mutants with at most 5 amino acid substitutions, (v)V H Including the above V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:7, and amino acid One HC-CDR2 containing column SEQ ID NO:14, and amino acid sequence SEQ ID It contains one HC-CDR3 containing NO:25, or at most 5 HC-CDRs. The mutant includes a variant containing a certain number of amino acid substitutions, (vi)V H Including the above V H The amino acid sequence One HC-CDR1 containing SEQ ID NO:8 and amino acid sequence SEQ ID N Contains one HC-CDR2 with O:19 and amino acid sequence SEQ ID NO:30 Contains one HC-CDR3, or HC-CDRs with at most five amino acid substitutions Includes variants, (vii)V H Including the above V HThis is the amino acid sequence SEQ ID N One HC-CDR1 containing O:3 and one containing amino acid sequence SEQ ID NO:15 One HC-CDR2 and one HC-CD containing amino acid sequence SEQ ID NO:26 Includes R3, or includes mutants in which HC-CDRs have at least 5 amino acid substitutions. (viii)V H Including the above V H This includes amino acid sequence SEQ ID NO:9. One HC-CDR1 and one HC-CD containing amino acid sequence SEQ ID NO:20 It contains R2 and one HC-CDR3 containing the amino acid sequence SEQ ID NO:31, Alternatively, the HC-CDRs may contain mutants with at most 5 amino acid substitutions, (ix)V H Including the above V H This is one HC-CDR containing amino acid sequence SEQ ID NO:10. 1, and one HC-CDR2 containing the amino acid sequence SEQ ID NO:21, and amino acids Includes one HC-CDR3 containing sequence SEQ ID NO:32, or HC-CD The mutant contains at most 5 amino acid substitutions in Rs, (x)V H Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:11, and amino acid sequence One HC-CDR2 containing SEQ ID NO:22, and amino acid sequence SEQ ID Contains one HC-CDR3 containing NO:33, or at most five HC-CDRs Includes mutants containing amino acid substitutions, or (xi)V H Including the above V H is, amino One HC-CDR1 containing the acid sequence SEQ ID NO:12, and the amino acid sequence SEQ One HC-CDR2 containing ID NO:23 and amino acid sequence SEQ ID NO:3 It contains one HC-CDR3 containing 4, or HC-CDRs containing at most 5 amino acids. Includes variants with acid substitution.

[0086] In some examples, the anti-Psl antibody is (i)V L Including the above V L is, One LC-CDR1 containing amino acid sequence SEQ ID NO:38 and amino acid sequence SE One LC-CDR2 containing Q ID NO:52 and amino acid sequence SEQ ID NO Includes one LC-CDR3 containing :63, or LC-CDRs containing at most 5 A (ii)V L Including the above V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:39, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 53 and one containing amino acid sequence SEQ ID NO:64 It contains LC-CDR3 or LC-CDRs containing at most 5 amino acid substitutions. (iii)V L Including the above V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 41 and one containing amino acid sequence SEQ ID NO:52 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:66 3 includes, or includes a mutant in which LC-CDRs have at least 5 amino acid substitutions, (iv)V L Including the above V L This is one amino acid sequence containing SEQ ID NO:42 LC-CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:55 It also contains one LC-CDR3 with amino acid sequence SEQ ID NO:67, and LC-CDRs include mutants containing at most 5 amino acid substitutions, (v)V L Includes , the aforementioned V L This includes one LC-CDR1 containing amino acid sequence SEQ ID NO:43, One LC-CDR2 containing amino acid sequence SEQ ID NO:56, and amino acid sequence S Includes one LC-CDR3 with EQ ID NO:68, or LC-CDRs (vi)V includes mutants containing at most 5 amino acid substitutions. L Including the above V L is, One LC-CDR1 containing amino acid sequence SEQ ID NO:44, and amino acid sequence SE One LC-CDR2 containing Q ID NO:57 and amino acid sequence SEQ ID NO Includes one LC-CDR3 containing :70, or LC-CDRs containing at most 5 A Includes mutants containing mino acid substitutions, (vii)V L Including the above V L This is the amino acid sequence SE One LC-CDR1 containing Q ID NO:45 and amino acid sequence SEQ ID NO One LC-CDR2 containing :58 and one containing amino acid sequence SEQ ID NO:71 It contains one LC-CDR3 or the LC-CDRs contain at most five amino acid substitutions. (viii)V L Including the above V L This is the amino acid sequence SEQ ID N Contains one LC-CDR1 with O:46 and amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC-C containing amino acid sequence SEQ ID NO:72 Contains DR3 or mutants containing at most 5 amino acid substitutions in LC-CDRs. Mi, (ix)V L Including the above V L This includes amino acid sequence SEQ ID NO:47. One LC-CDR1 and one LC-CD containing amino acid sequence SEQ ID NO:59 It contains R2 and one LC-CDR3 containing the amino acid sequence SEQ ID NO:73, Alternatively, the LC-CDRs may contain mutants with at most 5 amino acid substitutions, (x)V L of Including the aforementioned V L This is one LC-CDR1 containing amino acid sequence SEQ ID NO:48. And, one LC-CDR2 containing amino acid sequence SEQ ID NO:60, and amino acid Includes one LC-CDR3 containing column SEQ ID NO:74, or LC-CDR This includes mutants containing at most 5 amino acid substitutions in s, or (xi)V L Including the above V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:49, and amino One LC-CDR2 containing the acid sequence SEQ ID NO:61, and the amino acid sequence SEQ Includes one LC-CDR3 containing ID NO:75, or many LC-CDRs This also includes mutants containing five amino acid substitutions.

[0087] In some examples, the anti-Psl antibody is (i)V H and V L Including the above V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:2, and amino acids One HC-CDR2 containing sequence SEQ ID NO:14 and amino acid sequence SEQ I Contains one HC-CDR3 containing D NO:25, or more than HC-CDRs The variant includes a variant containing 5 amino acid substitutions, and the V LThis is the amino acid sequence SEQ ID NO One LC-CDR1 containing :38 and one containing amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC-CD containing amino acid sequence SEQ ID NO:63 Includes R3, or includes mutants in LC-CDRs that have at least 5 amino acid substitutions. (ii)V H and V L Including the above V H The amino acid sequence SEQ ID NO:3 It contains one HC-CDR1 and one HC containing amino acid sequence SEQ ID NO:15 -CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:26 Contains, or contains a variant of HC-CDRs having at least 5 amino acid substitutions, and the V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:39, and amino acids One LC-CDR2 containing sequence SEQ ID NO:53 and amino acid sequence SEQ I Includes one LC-CDR3 containing D NO:64, or at least one LC-CDRs. (iii)V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:5, and amino acid sequence S One HC-CDR2 containing EQ ID NO:17 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:28, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:41 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:52 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:66 It includes, or includes a mutant in which LC-CDRs have at least 5 amino acid substitutions, (i v)V H and V L Including the above V H This includes amino acid sequence SEQ ID NO:6. One HC-CDR1 and one HC-CD containing amino acid sequence SEQ ID NO:18 It contains R2 and one HC-CDR3 containing the amino acid sequence SEQ ID NO:29, Alternatively, the HC-CDRs may include a variant containing at least 5 amino acid substitutions, and the V L teeth, One LC-CDR1 containing amino acid sequence SEQ ID NO:42, and amino acid sequence S One LC-CDR2 containing EQ ID NO:55 and amino acid sequence SEQ ID N Includes one LC-CDR3 containing O:67, or at most five LC-CDRs Includes mutants containing amino acid substitutions, (v)V H and V L Including the above V H amino acids One HC-CDR1 containing sequence SEQ ID NO:7, and amino acid sequence SEQ ID One HC-CDR2 containing NO:14 and amino acid sequence SEQ ID NO:25 It contains one HC-CDR3 and at most five amino acids in the HC-CDRs. Includes variants including substitution, and the V L This is one containing amino acid sequence SEQ ID NO:43 LC-CDR1 and one LC-CDR containing amino acid sequence SEQ ID NO:56 It contains 2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:68, or LC-CDRs include mutants containing at most 5 amino acid substitutions, (vi)V H oh Call V L Including the above V H It contains one HCl with amino acid sequence SEQ ID NO:8 CDR1 and one HC-CDR2 containing the amino acid sequence SEQ ID NO:19, and It contains one HC-CDR3 containing the mino acid sequence SEQ ID NO:30, or HC -CDRs include mutants containing at most 5 amino acid substitutions, and the V L is an amino acid blend One LC-CDR1 containing column SEQ ID NO:44, and amino acid sequence SEQ ID One LC-CDR2 containing NO:57 and amino acid sequence SEQ ID NO:70 It contains one LC-CDR3 and, or LC-CDRs, at most five amino acids. Includes mutants that include substitution, (vii)V H and V L Including the above V H The amino acid sequence S One HC-CDR1 containing EQ ID NO:3 and amino acid sequence SEQ ID NO One HC-CDR2 containing :15 and one containing amino acid sequence SEQ ID NO:26 It contains one HC-CDR3 or the HC-CDRs contain at most five amino acid substitutions. Includes variants, and the V L This is one LC containing amino acid sequence SEQ ID NO:45 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:58, It contains one LC-CDR3 containing amino acid sequence SEQ ID NO:71, or L C-CDRs include mutants containing at most 5 amino acid substitutions, (viii)V H Oh bi V L Including the above V H This is one HC-C containing amino acid sequence SEQ ID NO:9 DR1, one HC-CDR2 containing amino acid sequence SEQ ID NO:20, and It contains one HC-CDR3 containing the noacid sequence SEQ ID NO:31, or HC- The CDRs include mutants containing at most 5 amino acid substitutions, and the V L The amino acid sequence One LC-CDR1 containing SEQ ID NO:46, and amino acid sequence SEQ ID Contains one LC-CDR2 with NO:52 and amino acid sequence SEQ ID NO:72 It contains one LC-CDR3 or at most five amino acid substitutions in the LC-CDRs. Includes variants containing (ix)V H and V L Including the above V H This is the amino acid sequence SEQ One HC-CDR1 containing ID NO:10, and amino acid sequence SEQ ID NO: One HC-CDR2 containing 21 and one containing amino acid sequence SEQ ID NO:32 It contains HC-CDR3 or HC-CDRs containing at most 5 amino acid substitutions. Includes variants, and V L This is one LC- containing amino acid sequence SEQ ID NO:47 CDR1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:59, and It contains one LC-CDR3 containing the mino acid sequence SEQ ID NO:73, or LC -CDRs include mutants with at most 5 amino acid substitutions, (x)V H and V L of Including the aforementioned V H This is one HC-CDR1 containing amino acid sequence SEQ ID NO:11. And, one HC-CDR2 containing amino acid sequence SEQ ID NO:22, and amino acid Includes one HC-CDR3 containing column SEQ ID NO:33, or HC-CDR The mutant includes at most 5 amino acid substitutions in s, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:48, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 60 and one containing amino acid sequence SEQ ID NO:74 It contains LC-CDR3 or LC-CDRs containing at most 5 amino acid substitutions. Includes mutants, or (xi)V H and V L Including the above V H This is the amino acid sequence SE One HC-CDR1 containing Q ID NO:12 and amino acid sequence SEQ ID NO One HC-CDR2 containing :23 and one containing amino acid sequence SEQ ID NO:34 It contains one HC-CDR3 or the HC-CDRs contain at most five amino acid substitutions. Includes variants, and the V L This is one LC containing amino acid sequence SEQ ID NO:49 -CDR1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:61, It contains one LC-CDR3 containing amino acid sequence SEQ ID NO:75, or L The C-CDRs include mutants containing at most five amino acid substitutions.

[0088] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth SEQ ID NOs: One of the following meshes: 80-81, 83-90, and 159 No acid sequence, or SEQ ID NOs: 80-81, 83-90, and 159 Any one amino acid sequence and at least 90% (for example, at least 91%, 92%, 93%) mutants with sequence identity of 94%, 95%, 96%, 97%, 98%, or 99%. Includes array, the V L This refers to SEQ ID NOs: 92-93, 95-97, and 99 -104, any one of the amino acid sequences, or SEQ ID NOs: 92-93, 9 One of the amino acid sequences 5-97 and 99-104 and at least 90% (for example) or at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or It includes mutant sequences having 99% sequence identity. In some examples, the anti-P The sl antibody is one of the following SEQ ID NOs: 80-81, 83-90, and 159. V containing one amino acid sequence H And, SEQ ID NOs: 92-93, 95-97, V containing one of the amino acid sequences 99-104 L This includes.

[0089] In some embodiments, the anti-Psl antibody is a full-length antibody. In some examples, the anti-Psl antibody includes the IgG1 constant region. In some examples, the IgG1 refers to human IgG1. This includes the IgG4 constant region. In some examples, the IgG4 is human IgG This refers to 4. In some examples, the heavy chain constant region of the anti-Psl antibody is composed of amino acids. The column contains SEQ ID NO:160, or the amino acid sequence contains SEQ ID NO:16 It consists of 0. In some examples, the heavy chain constant region of the anti-Psl antibody is an amino acid Contains sequence SEQ ID NO:161 or amino acid sequence SEQ ID NO:1 It consists of 61. In some examples, the light chain constant region of the anti-Psl antibody is amino Contains acid sequence SEQ ID NO:162, or amino acid sequence SEQ ID NO: It consists of 162.

[0090] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth V with SEQ ID NO:80 H HC-CDR1, HC-CDR2 and The V L V has SEQ ID NO:92 L in Includes LC-CDR1, LC-CDR2, and LC-CDR3. In some examples, The anti-Psl antibody is V H and V L Including the above V H SEQ ID NO:8 V having 1 H This includes HC-CDR1, HC-CDR2, and HC-CDR3 in the above. The aforementioned V L V has SEQ ID NO:93 L LC-CDR1, LC-C It includes DR2 and LC-CDR3. In some examples, the anti-Psl antibody is V H and V L Including the above V H V has SEQ ID NO:83 H H in Includes C-CDR1, HC-CDR2 and HC-CDR3, and the V L is SEQ ID V with NO:95 L LC-CDR1, LC-CDR2 and LC-CDR Includes 3. In some examples, the anti-Psl antibody is V H and V L Including, before Record V HV has SEQ ID NO:84 H HC-CDR1, HC-CD Includes R2 and HC-CDR3, and V L V has SEQ ID NO:96 L This includes LC-CDR1, LC-CDR2, and LC-CDR3 in several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H is SEQ ID V with NO:85 H HC-CDR1, HC-CDR2 and HC-CDR3 Including the above V L V has SEQ ID NO:97 L LC-CDR1 in Includes LC-CDR2 and LC-CDR3. In some embodiments, the anti-Psl Antibodies are V H and V L Including the above V H V has SEQ ID NO:86 H to The V L SE V with Q ID NO:99 L LC-CDR1, LC-CDR2 and LC -Contains CDR3. In some examples, the anti-Psl antibody is V H and V L of Including the aforementioned V H V has SEQ ID NO:81 H HC-CDR1, H Includes C-CDR2 and HC-CDR3, and the V L SEQ ID NO:100 possessing V L This includes LC-CDR1, LC-CDR2, and LC-CDR3. In several examples, the anti-Psl antibody is V H and V L Including the above V H SE V with Q ID NO:87 H HC-CDR1, HC-CDR2 and HC -Includes CDR3, the V L V has SEQ ID NO:101 L LC in -Includes CDR1, LC-CDR2, and LC-CDR3. In some embodiments, The aforementioned anti-Psl antibody is V H and V L Including the above V H SEQ ID NO:88 possessing V H This includes HC-CDR1, HC-CDR2, and HC-CDR3 in the above. V L V has SEQ ID NO:102 L LC-CDR1, LC-CD It includes R2 and LC-CDR3. In some examples, the anti-Psl antibody is V H and V L Including the above V H V has SEQ ID NO:89 H HC in -Includes CDR1, HC-CDR2 and HC-CDR3, and the V L is SEQ ID V with NO:103 L LC-CDR1, LC-CDR2 and LC-CDR Includes 3. In some examples, the anti-Psl antibody is V H and V L Including, before Record V H V has SEQ ID NO:90 H HC-CDR1, HC-CD Includes R2 and HC-CDR3, and V LV has SEQ ID NO:104 L This includes LC-CDR1, LC-CDR2, and LC-CDR3 in several actual In the embodiment, the anti-Psl antibody is V H and V L Including the above V H is SEQ ID V with NO:159 H HC-CDR1, HC-CDR2 and HC-CD in R3 is included, and V L V has SEQ ID NO:95 L LC-CDR 1. Includes LC-CDR2 and LC-CDR3.

[0091] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:13 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:24, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:37 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:51 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0092] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:2, and amino acid sequence S One HC-CDR2 containing EQ ID NO:14 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:25, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:38 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:52 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:63 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0093] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:2, and amino acid sequence S One HC-CDR2 containing EQ ID NO:14 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:25, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:38 and amino acid sequence SEQ ID NO:52 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:63 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:2, and amino acid sequence SE One HC-CDR2 containing Q ID NO:14 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :25, and the V LThis is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:38 and amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:63 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:2 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:14 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:25. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:38 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and amino acid sequence One LC-CDR3 containing SEQ ID NO:63 and the same epitope as the antibody It provides a binding anti-Psl antibody.

[0094] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:80, or amino acid sequence SEQ ID NO:8 0 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:92, or amino acid sequence SEQ ID NO: 92 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:80 Mu V H V containing amino acid sequence SEQ ID NO:92 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:80 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:92. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0095] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence S One HC-CDR2 containing EQ ID NO:15 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:26, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:39 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:53 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:64 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0096] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence S One HC-CDR2 containing EQ ID NO:15 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:26, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:39 and amino acid sequence SEQ ID NO:53 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:64 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence SE One HC-CDR2 containing Q ID NO:15 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :26, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 including NO:39 and amino acid sequence SEQ ID NO:53 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:64 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:3 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:15 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:26. M, the aforementioned V LIt contains one LC-CDR1 with amino acid sequence SEQ ID NO:39 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:53, and amino acid sequence One LC-CDR3 containing SEQ ID NO:64 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0097] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:81, or amino acid sequence SEQ ID NO:8 1 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:93, or amino acid sequence SEQ ID NO: 93 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:81 Mu V H And V containing amino acid sequence SEQ ID NO:93 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:81 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:93. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0098] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:5, and amino acid sequence S One HC-CDR2 containing EQ ID NO:17 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:28, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:41 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:52 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:66 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0099] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:5, and amino acid sequence S One HC-CDR2 containing EQ ID NO:17 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:28, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:41 and amino acid sequence SEQ ID NO:52 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:66 -Includes CDR3. In some embodiments, V H and V L Including the above VH teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:5, and amino acid sequence SE One HC-CDR2 containing Q ID NO:17 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :28, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:41 and amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:66 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:5 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:17 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:28. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:41 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and amino acid sequence One LC-CDR3 containing SEQ ID NO:66 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0100] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:83, or amino acid sequence SEQ ID NO:8 3 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:95, or amino acid sequence SEQ ID NO: 95 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:83 Mu V H V containing amino acid sequence SEQ ID NO:95 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:83 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:95. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0101] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:159, or amino acid sequence SEQ ID NO: 159 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:95, or amino acid sequence SEQ ID N O:95 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:15 V including 9 H V containing amino acid sequence SEQ ID NO:95 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:159 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:95 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0102] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:6, and amino acid sequence S One HC-CDR2 containing EQ ID NO:18 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:29, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:42 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:55 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:67 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0103] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:6, and amino acid sequence S One HC-CDR2 containing EQ ID NO:18 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:29, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:42 and amino acid sequence SEQ ID NO:55 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:67 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:6, and amino acid sequence SE One HC-CDR2 containing Q ID NO:18 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :29, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:42 and amino acid sequence SEQ ID NO:55 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:67 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:6 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:18 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:29. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:42 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:55, and amino acid sequence One LC-CDR3 containing SEQ ID NO:67 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0104] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:84, or amino acid sequence SEQ ID NO:8 4 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:96, or amino acid sequence SEQ ID NO: 96 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:84 Mu V H And V containing amino acid sequence SEQ ID NO:96 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:84 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:96. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0105] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:7, and amino acid sequence S One HC-CDR2 containing EQ ID NO:14 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:25, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:43 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:56 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:68 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0106] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:7, and amino acid sequence S One HC-CDR2 containing EQ ID NO:14 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:25, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:43 and amino acid sequence SEQ ID NO:56 Contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:68 -Includes CDR3. In some embodiments, V H and V LIncluding the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:7, and amino acid sequence SE One HC-CDR2 containing Q ID NO:14 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :25, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 including NO:43 and amino acid sequence SEQ ID NO:56 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:68 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:7 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:14 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:25. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:43 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:56, and amino acid sequence One LC-CDR3 containing SEQ ID NO:68 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0107] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:85, or amino acid sequence SEQ ID NO:8 5 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:97, or amino acid sequence SEQ ID NO: 97 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:85 Mu V H And V containing amino acid sequence SEQ ID NO:97 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:85 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:97. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0108] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:8, and amino acid sequence S One HC-CDR2 containing EQ ID NO:19 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:30, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:44 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:57 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:70 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0109] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:8, and amino acid sequence S One HC-CDR2 containing EQ ID NO:19 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:30, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:44 and amino acid sequence SEQ ID NO:57 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:70 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:8, and amino acid sequence SE One HC-CDR2 containing Q ID NO:19 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :30, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:44 and amino acid sequence SEQ ID NO:57 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:70 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V LIncluding the above V H It contains amino acid sequence SEQ ID NO:8 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:19 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:30. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:44 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:57, and amino acid sequence One LC-CDR3 containing SEQ ID NO:70 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0110] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:86, or amino acid sequence SEQ ID NO:8 6 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:99, or amino acid sequence SEQ ID NO: 99 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:86 Mu V H And V containing amino acid sequence SEQ ID NO:99 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V HThe amino acid sequence S V with EQ ID NO:86 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is V, which has amino acid sequence SEQ ID NO:99. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0111] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence S One HC-CDR2 containing EQ ID NO:15 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:26, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:45 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:58 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:71 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0112] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence S One HC-CDR2 containing EQ ID NO:15 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:26, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:45 and amino acid sequence SEQ ID NO:58 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:71 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:3, and amino acid sequence SE One HC-CDR2 containing Q ID NO:15 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :26, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:45 and amino acid sequence SEQ ID NO:58 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:71 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:3 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:15 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:26. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:45 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:58, and amino acid sequence An antibody containing one LC-CDR3 with SEQ ID NO:71 in the same epitope It provides a binding anti-Psl antibody.

[0113] In some examples, the anti-Psl antibody is V H and V LIncluding the above V H teeth , amino acid sequence SEQ ID NO:81, or amino acid sequence SEQ ID NO:8 1 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:100, or amino acid sequence SEQ ID NO :100 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:81 V including H V containing amino acid sequence SEQ ID NO:100 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:81 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:100 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0114] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:9, and amino acid sequence S One HC-CDR2 containing EQ ID NO:20 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:31, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:46 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:52 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:72 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0115] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:9, and amino acid sequence S One HC-CDR2 containing EQ ID NO:20 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:31, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:46 and amino acid sequence SEQ ID NO:52 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:72 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:9, and amino acid sequence SE One HC-CDR2 containing Q ID NO:20 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :31, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 including NO:46 and amino acid sequence SEQ ID NO:52 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:72 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:9 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:20 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:31. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:46 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:52, and amino acid sequence One LC-CDR3 containing SEQ ID NO:72 and the same epitope as the antibody It provides a binding anti-Psl antibody.

[0116] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:87, or amino acid sequence SEQ ID NO:8 7 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 101, or amino acid sequence SEQ ID NO :101 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:87 V including H And V containing amino acid sequence SEQ ID NO:101 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:87 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:101 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0117] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:10, and amino acid sequence One HC-CDR2 containing SEQ ID NO:21 and amino acid sequence SEQ ID Contains one HC-CDR3 containing NO:32, or at most five HC-CDRs The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 7 and one containing amino acid sequence SEQ ID NO:59 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:73 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0118] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:10, and amino acid sequence One HC-CDR2 containing SEQ ID NO:21 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:32, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:47 and amino acid sequence SEQ ID NO:59 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:73 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:10, and amino acid sequence One HC-CDR2 containing SEQ ID NO:21 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:32, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:47 and amino acid sequence SEQ ID NO:59 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:73 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:1 One HC-CDR1 containing 0 and one containing amino acid sequence SEQ ID NO:21 HC-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:32 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:47 R1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:59, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:73 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0119] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:88, or amino acid sequence SEQ ID NO:8 8 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 102, or amino acid sequence SEQ ID NO :102 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:88 V including H V containing amino acid sequence SEQ ID NO:102 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:88 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:102 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0120] In some examples, the anti-Psl antibody is VH and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:11, and amino acid sequence One HC-CDR2 containing SEQ ID NO:22, and amino acid sequence SEQ ID Contains one HC-CDR3 containing NO:33, or at most five HC-CDRs The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 8 and one containing amino acid sequence SEQ ID NO:60 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:74 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0121] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:11, and amino acid sequence One HC-CDR2 containing SEQ ID NO:22, and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:33, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:48 and amino acid sequence SEQ ID NO:60 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:74 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:11, and amino acid sequence One HC-CDR2 containing SEQ ID NO:22, and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:33, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:48 and amino acid sequence SEQ ID NO:60 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:74 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:1 One HC-CDR1 containing 1 and one containing amino acid sequence SEQ ID NO:22 HC-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:33 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:48 R1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:60, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:74 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0122] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:89, or amino acid sequence SEQ ID NO:8 9 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 103, or amino acid sequence SEQ ID NO :103 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:89 V including H And V containing amino acid sequence SEQ ID NO:103 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:89 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:103 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0123] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:12, and amino acid sequence One HC-CDR2 containing SEQ ID NO:23 and amino acid sequence SEQ ID Contains one HC-CDR3 containing NO:34, or at most five HC-CDRs The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 9 and one containing amino acid sequence SEQ ID NO:61 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:75 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0124] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:12, and amino acid sequence One HC-CDR2 containing SEQ ID NO:23 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:34, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:49 and amino acid sequence SEQ ID NO:61 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:75 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:12, and amino acid sequence One HC-CDR2 containing SEQ ID NO:23 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:34, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:49 and amino acid sequence SEQ ID NO:61 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:75 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:1 One HC-CDR1 containing 2 and one containing amino acid sequence SEQ ID NO:23 HC-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:34 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:49 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:61, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:75 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0125] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:90, or amino acid sequence SEQ ID NO:9 0 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 104, or amino acid sequence SEQ ID NO :104 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:90 V including H And V containing amino acid sequence SEQ ID NO:104 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO: 90 H HC-CDR1, HC-CDR2 and HC-CDR3, and the VL It has the amino acid sequence SEQ ID NO:104 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0126] In one aspect of the present invention, V H and V L Including the above V H IHSVH (SEQ ID NO:4) or its variants, the variants containing at most 3 amino acid substitutions One HC-CDR1 and TIISSGTTTTYAQSFQD(SEQ I D NO:16) or its variants, wherein the variants have at most three amino acid substitutions It includes one HC-CDR2 and X1X2X3X4 (SEQ ID NO:18 9) Including a variant thereof, the variant containing at most three amino acid substitutions Here, X1 is D, Y, or N, X2 is G or A, and X3 is D or T X4 includes one HC-CDR3 which is S, A, or T, and the V L , RA Includes SQGISSWLA (SEQ ID NO: 40) or its variants, and the variants One LC-CDR1 contains at most three amino acid substitutions, and HASTLE S (SEQ ID NO: 54) or its variants, and the variants include at most 3 One LC-CDR2 containing amino acid substitutions and LQAX1SLPHT(SEQ ID NO:158) or its variants, and the aforementioned variants contain at most 3 amino acids. This includes substitutions, where X1 is N, D, Y, F, P, G, K, H, A, C, E, Isolated anti-P containing one LC-CDR3 which is Q, R, S, T, V, W, or L We provide SL antibodies.

[0127] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth V with SEQ ID NO:82 H HC-CDR1, HC-CDR2 and The V L V has SEQ ID NO:94 L in Includes LC-CDR1, LC-CDR2, and LC-CDR3. In some examples, The anti-Psl antibody is V H and V L Including the above V H SEQ ID NO:1 V with 05 H Includes HC-CDR1, HC-CDR2, and HC-CDR3 in , the aforementioned V L V has SEQ ID NO:94 L LC-CDR1, LC- It includes CDR2 and LC-CDR3. In some examples, the anti-Psl antibody is , V H and V L Including the above V H V has SEQ ID NO:106 H ni oke Includes HC-CDR1, HC-CDR2 and HC-CDR3, and the V L SEQ V with ID NO:94 L LC-CDR1, LC-CDR2 and LC-C Contains DR3. In some examples, the anti-Psl antibody is V H and V L Includes , the aforementioned V H V has SEQ ID NO:107 H HC-CDR1, HC -Includes CDR2 and HC-CDR3, and the VL It has SEQ ID NO:94 ru V L This includes LC-CDR1, LC-CDR2, and LC-CDR3. In the example, the anti-Psl antibody is V H and V L Including the above V H SEQ V with ID NO:108 H HC-CDR1, HC-CDR2 and HC- Includes CDR3, the V L V has SEQ ID NO:94 L LC-C in Includes DR1, LC-CDR2, and LC-CDR3. In some embodiments, the above Anti-Psl antibodies are V H and V L Including the above V H It has SEQ ID NO:109 do V H This includes HC-CDR1, HC-CDR2 and HC-CDR3 in the above V L V has SEQ ID NO:94 L LC-CDR1, LC-CDR2 and LC-CDR3. In some examples, the anti-Psl antibody is V H oh Call V L Including the above V H V has SEQ ID NO:110 H HC- Includes CDR1, HC-CDR2 and HC-CDR3, and the V L SEQ ID N V with O:94 L LC-CDR1, LC-CDR2 and LC-CDR3 in Includes. In some examples, the anti-Psl antibody is V H and V L Including the above V HV has SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L V has SEQ ID NO:111 L to This includes LC-CDR1, LC-CDR2, and LC-CDR3. Several examples In this case, the anti-Psl antibody is V H and V L Including the above V H SEQ ID N V with O:82 H HC-CDR1, HC-CDR2 and HC-CDR3 in Including the aforementioned V L This is V with SEQ ID NO:112 L LC-CDR1 in Includes LC-CDR2 and LC-CDR3. In some embodiments, the anti-Psl Antibodies are V H and V L Including the above V H V has SEQ ID NO:82 H to The V L SE V with Q ID NO:113 L LC-CDR1, LC-CDR2 and L Contains C-CDR3. In some examples, the anti-Psl antibody is V H and V L Including the above V H V has SEQ ID NO:82 H HC-CDR1 in Including HC-CDR2 and HC-CDR3, the V L SEQ ID NO:114 A prominent V L This includes LC-CDR1, LC-CDR2, and LC-CDR3. In several examples, the anti-Psl antibody was V H and V L Including the above V H is, S V with EQ ID NO:82 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is V with SEQ ID NO:115 L L in Includes C-CDR1, LC-CDR2, and LC-CDR3. In some embodiments... The anti-Psl antibody is V H and V L Including the above V H SEQ ID NO:82 A prominent V H This includes HC-CDR1, HC-CDR2, and HC-CDR3, and the preceding Record V L This is V with SEQ ID NO:116 L LC-CDR1, LC-C It includes DR2 and LC-CDR3. In some examples, the anti-Psl antibody is V H and V L Including the above V H V has SEQ ID NO:82 H H in Includes C-CDR1, HC-CDR2 and HC-CDR3, and the V L is SEQ ID V with NO:117 L LC-CDR1, LC-CDR2 and LC-CD in Includes R3. In some examples, the anti-Psl antibody is V H and V L Includes, The aforementioned V H V has SEQ ID NO:82 H HC-CDR1, HC-C Including DR2 and HC-CDR3, the V LIt has SEQ ID NO:118 V L This includes LC-CDR1, LC-CDR2, and LC-CDR3 in several. In the example, the anti-Psl antibody is V H and V L Including the above V H SEQ I D NO:82 has V H HC-CDR1, HC-CDR2 and HC-CD in R3 is included, and V L V has SEQ ID NO:119 L LC-CD Includes R1, LC-CDR2 and LC-CDR3. In some embodiments, the anti Psl antibody is V H and V L Including the above V H It has SEQ ID NO:82 V H This includes HC-CDR1, HC-CDR2 and HC-CDR3 in the above V L teeth V with SEQ ID NO:120 L LC-CDR1, LC-CDR2 It includes and LC-CDR3. In some examples, the anti-Psl antibody is V H Oh bi V L Including the above V H V has SEQ ID NO:82 H HC-CD in R1, HC-CDR2 and HC-CDR3 are included, and the V L SEQ ID NO: V with 121 L Includes LC-CDR1, LC-CDR2, and LC-CDR3 in Hmm. In some examples, the anti-Psl antibody was V H and V L Including the above V H V has SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L This is V with SEQ ID NO:122 L odor This includes LC-CDR1, LC-CDR2, and LC-CDR3. In some embodiments... In this context, the anti-Psl antibody is V H and V L Including the above V H is SEQ ID NO :82 has V H Includes HC-CDR1, HC-CDR2, and HC-CDR3 in M, the aforementioned V L V has SEQ ID NO:123 L LC-CDR1, L Includes C-CDR2 and LC-CDR3. In some embodiments, the anti-Psl anti The body is V H and V L Including the above V H V has SEQ ID NO:82 H odor Includes HC-CDR1, HC-CDR2 and HC-CDR3, and the V L SEQ V with ID NO:124 L LC-CDR1, LC-CDR2 and LC -Contains CDR3. In some examples, the anti-Psl antibody is V H and V L of Including the aforementioned V H V has SEQ ID NO:82 H HC-CDR1, H Includes C-CDR2 and HC-CDR3, and the V L SEQ ID NO:125 possessing V L This includes LC-CDR1, LC-CDR2, and LC-CDR3. In some embodiments, the anti-Psl antibody comprises V H and V L and the V H comprises HC-CDR1, HC-CDR2 and HC -CDR3 in V having SEQ ID NO:82, and the V H comprises LC-CDR1, LC-CDR2 and LC-CDR3 in V having SEQ ID NO:126. In some embodiments, the anti-Psl antibody comprises V[[ID=二十一]] H and V L and the V H comprises HC-CDR1, HC-CDR2 and HC-CDR3 in V having SEQ ID NO:82, and the V H comprises LC-CDR1, LC-CDR2 and LC-CDR3 in V having SEQ ID NO:127. In some embodiments, the anti-Psl antibody comprises V V L ’sV L comprises LC-CDR1, LC-CD R2 and LC-CDR3. In some embodiments, the anti-Psl antibody comprises V H and V L and the V H comprises HC-CDR1, HC-CDR2 and HC-CDR3 in V having SEQ ID NO:107, and the V H comprises LC-CDR1, LC-CDR and LC-CDR3 in V having SEQ ID NO:113. In some embodiments, the anti-Psl antibody comprises V L is SEQ ID NO:113 has V L comprises LC-CDR1, LC-CDR2 and LC-CD R3. In some embodiments, the anti-Psl antibody comprises V H and V L and the V[[ID=六十四]] H comprises HC-CDR1, HC- H CDR2 and HC-CDR3 in V having SEQ ID NO:107, and the V L ​​​​​​​​It has SEQ ID NO:123 ru V L This includes LC-CDR1, LC-CDR2, and LC-CDR3. In the example, the anti-Psl antibody is V H and V L Including the above V H SEQ V with ID NO:107 H HC-CDR1, HC-CDR2 and HC- Includes CDR3, the V L This is V with SEQ ID NO:116 L LC- Includes CDR1, LC-CDR2, and LC-CDR3.

[0128] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0129] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:65 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :27, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:65 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:65 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0130] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID NO: 94 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:82 Mu V H And V containing amino acid sequence SEQ ID NO:94 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:82 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:94. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0131] In some examples, the anti-Psl antibody is VH and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:165, or at most five HC-CDRs. The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 0 and one containing amino acid sequence SEQ ID NO:54 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0132] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:165, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:165, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:165 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:40 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:54, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:65 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0133] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:105, or amino acid sequence SEQ ID NO: 105 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and mutant sequences having at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95 %, 96%, 97%, 98% or 99%) sequence identity. In some embodiments, the anti-Psl antibody comprises V comprising amino acid sequence SEQ ID NO: 10 H and V L comprising amino acid sequence SEQ ID NO: 94. In some embodiments, the anti-Psl antibody comprises V H and V L wherein the V H comprises HC-CDR1, HC-CDR2 and HC-CDR3 in V H having amino acid sequence SEQ ID NO: 105, and the V comprises LC-CDR1, LC-CDR2 and LC-CDR3 in V L having amino acid sequence SEQ ID NO: 94. In some embodiments, the anti-Psl antibody comprises V L and V

[0134] wherein the V H comprises one HC-CDR1 comprising amino acid sequence SEQ ID NO: 4, one HC-CDR2 comprising amino acid sequence S L EQ ID NO: 16, and one HC-CDR3 comprising amino acid sequence SEQ ID N H O: 166, or mutants having at most 5 amino acid substitutions in the HC-CDRs, and the V comprises one LC-CDR1 comprising amino acid sequence SEQ ID NO: 4​​​​​​​​​​​​​This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0135] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:166, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:166, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:166 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:40 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:54, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:65 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0136] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 106, or amino acid sequence SEQ ID NO: 106 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:10 V including 6 H And V containing amino acid sequence SEQ ID NO:94 L Includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H is an amino acid blend V with column SEQ ID NO:106 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:94 ru V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0137] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:35, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0138] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:35, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:65 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :35, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:65 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:35. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:65 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0139] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 107, or amino acid sequence SEQ ID NO: 107 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:10 V including 7 H And V containing amino acid sequence SEQ ID NO:94 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:107 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:94 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0140] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:167, or at most five HC-CDRs. The variant includes the amino acid substitution of the V LThis is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 0 and one containing amino acid sequence SEQ ID NO:54 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0141] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:167, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:167, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:167 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:40 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:54, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:65 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0142] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:108, or amino acid sequence SEQ ID NO: 108 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:10 V including 8 H And V containing amino acid sequence SEQ ID NO:94 L This includes several. In the example, the anti-Psl antibody is VH and V L Including the above V H amino acids V with sequence SEQ ID NO:108 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:94 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0143] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:168, or at most five HC-CDRs. The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 0 and one containing amino acid sequence SEQ ID NO:54 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0144] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:168, and the VL This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:168, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:168 and the above V L This is one LC-CD containing amino acid sequence SEQ ID NO:40 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:54, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:65 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0145] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:109, or amino acid sequence SEQ ID NO: 109 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:10 V including 9 H And V containing amino acid sequence SEQ ID NO:94 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:109 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:94 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0146] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:199 This includes, or includes mutants in which the LC-CDRs contain at most 5 amino acid substitutions.

[0147] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:199 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:199 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:199 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0148] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 111, or amino acid sequence SEQ ID NO :111 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:111 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:111 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0149] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:200 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0150] In some examples, the anti-Psl antibody is V H and V L Including the above VH teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:200 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:200 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:200 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0151] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 112, or amino acid sequence SEQ ID NO :112 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:112 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:112 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0152] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:76 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0153] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:76 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :27, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:76 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:76 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0154] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 113, or amino acid sequence SEQ ID NO :113 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:113 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:113 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0155] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:201 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0156] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:201 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:201 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:201 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0157] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 114, or amino acid sequence SEQ ID NO :114 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:114 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:114 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0158] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:202 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0159] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:202 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:202 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:202 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0160] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 115, or amino acid sequence SEQ ID NO :115 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:115 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:115 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0161] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:78 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0162] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:78 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :27, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:78 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:78 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0163] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 116, or amino acid sequence SEQ ID NO :116 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:116 LThis includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:116 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0164] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:203 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0165] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:203 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:203 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:203 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0166] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 117, or amino acid sequence SEQ ID NO :117 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:117 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:117 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0167] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:204 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0168] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:204 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:204 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:204 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0169] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 118, or amino acid sequence SEQ ID NO :118 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:118 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:118 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0170] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:205 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0171] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:205 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:205 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V LThis is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:205 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0172] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 119, or amino acid sequence SEQ ID NO :119 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:119 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:119 do V LThis includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0173] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:206 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0174] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:206 Includes C-CDR3. In some examples, V H and V L Including the above VH teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:206 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:206 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0175] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:120, or amino acid sequence SEQ ID NO :120 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H V containing amino acid sequence SEQ ID NO:120 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:120 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0176] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:207 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0177] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:207 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:207 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V LIncluding the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:207 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0178] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 121, or amino acid sequence SEQ ID NO :121 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:121 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above VH amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:121 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0179] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:208 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0180] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:208 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:208 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:208 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0181] In some examples, the anti-Psl antibody is V H and V LIncluding the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 122, or amino acid sequence SEQ ID NO :122 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:122 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:122 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0182] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:77 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0183] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:77 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :27, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:77 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:77 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0184] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 123, or amino acid sequence SEQ ID NO :123 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:123 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has the amino acid sequence SEQ ID NO:123 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0185] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:209 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0186] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:209 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:209 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:209 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0187] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 124, or amino acid sequence SEQ ID NO :124 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:124 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:124 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0188] In some examples, the anti-Psl antibody is VH and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:210 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0189] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:210 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:210 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:210 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0190] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 125, or amino acid sequence SEQ ID NO :125 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:125 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:125 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0191] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:35, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:78 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0192] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:35, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:78 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :35, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:78 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:35. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:78 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0193] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 126, or amino acid sequence SEQ ID NO :126 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:126 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the VL It has amino acid sequence SEQ ID NO:126 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0194] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:27, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:212 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0195] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:212 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:27, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 Contains one LC-CDR2 and one L containing amino acid sequence SEQ ID NO:212 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:27 Including the above V L This is one LC-CDR containing amino acid sequence SEQ ID NO:40 1, and one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acids The antibody containing one LC-CDR3 with sequence SEQ ID NO:212 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0196] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:82, or amino acid sequence SEQ ID NO:8 2 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO: 127, or amino acid sequence SEQ ID NO :127 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:82 V including H And V containing amino acid sequence SEQ ID NO:127 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:82 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:127 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0197] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:35, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V LThis is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:76 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0198] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:35, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:76 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :35, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:76 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:35. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:76 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0199] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 107, or amino acid sequence SEQ ID NO: 107 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This is the amino acid sequence SEQ ID NO:113, or the amino acid sequence SEQ ID NO:113 and at least 90% (for example, at least 91%, 92%, 93%, 94%) Includes variant sequences with sequence identity of 95%, 96%, 97%, 98%, or 99%. In some examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO: V including 107 H And V containing amino acid sequence SEQ ID NO:113 L It includes. In several examples, the anti-Psl antibody was VH and V L Including the above V H is, V with mino acid sequence SEQ ID NO:107 H HC-CDR1, HC-C Including DR2 and HC-CDR3, the V L This is the amino acid sequence SEQ ID NO:1 V with 13 L Includes LC-CDR1, LC-CDR2, and LC-CDR3 in .

[0200] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:35, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:77 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0201] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:35, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:77 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :35, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:77 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:35. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:77 and the same epitope as the antibody containing It provides a binding anti-Psl antibody.

[0202] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 107, or amino acid sequence SEQ ID NO: 107 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This is the amino acid sequence SEQ ID NO:123, or the amino acid sequence SEQ ID NO:123 and at least 90% (for example, at least 91%, 92%, 93%, 94%) Includes variant sequences with sequence identity of 95%, 96%, 97%, 98%, or 99%. In some examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO: V including 107 H And V containing amino acid sequence SEQ ID NO:123 L It includes. In several examples, the anti-Psl antibody was V H and V L Including the above V H is, V with mino acid sequence SEQ ID NO:107 H HC-CDR1, HC-C Including DR2 and HC-CDR3, the V L This is the amino acid sequence SEQ ID NO:1 V with 23 L Includes LC-CDR1, LC-CDR2, and LC-CDR3 in .

[0203] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:35, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:40 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:54 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:78 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0204] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:35, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:40 and amino acid sequence SEQ ID NO:54 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:78 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence SE One HC-CDR2 containing Q ID NO:16 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :35, and the V LThis is the amino acid sequence SEQ ID Contains one LC-CDR1 with NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:78 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:4 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:16 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:35. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:40 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:54, and amino acid sequence One LC-CDR3 containing SEQ ID NO:78 and the same epitope as the antibody containing it It provides a binding anti-Psl antibody.

[0205] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 107, or amino acid sequence SEQ ID NO: 107 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This is the amino acid sequence SEQ ID NO:116, or the amino acid sequence SEQ ID NO:116 and at least 90% (for example, at least 91%, 92%, 93%, 94%) Includes variant sequences with sequence identity of 95%, 96%, 97%, 98%, or 99%. In some examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO: V including 107 H And V containing amino acid sequence SEQ ID NO:116 L It includes. In several examples, the anti-Psl antibody was V H and V L Including the above V H is, V with mino acid sequence SEQ ID NO:107 H HC-CDR1, HC-C Including DR2 and HC-CDR3, the V L This is the amino acid sequence SEQ ID NO:1 V with 16 L Includes LC-CDR1, LC-CDR2, and LC-CDR3 in .

[0206] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:169, or at most five HC-CDRs. The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:4 One LC-CDR1 containing 0 and one containing amino acid sequence SEQ ID NO:54 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:65 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0207] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:169, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:4, and amino acid sequence S One HC-CDR2 containing EQ ID NO:16 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:169, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:40 and amino acid sequence SEQ ID NO:54 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:65 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:4 One HC-CDR1 containing and one H containing amino acid sequence SEQ ID NO:16 C-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:169 and the V LThis is one LC-CD containing amino acid sequence SEQ ID NO:40 R1 and one LC-CDR2 containing the amino acid sequence SEQ ID NO:54, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:65 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0208] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:110, or amino acid sequence SEQ ID NO: 110 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:94, or amino acid sequence SEQ ID N O:94 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:11 V including 0 H And V containing amino acid sequence SEQ ID NO:94 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:110 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:94 do V LThis includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0209] In one aspect of the present invention, V H and V L Including the above V H SSGDYWG(SEQ ID NO:1) or its variants, wherein the variants have at most three amino acid substitutions It includes one HC-CDR1 and SIHNX1GSTYYNPSLKG(SEQ ID NO:213) or its variants, and the aforementioned variants contain at most 3 amino acids. This involves substitution, where X1 is one HC-CDR2 and X1 is S, K, or Q. Includes QFGSETYYX1GIX2P (SEQ ID NO:190) or its variants. Furthermore, the aforementioned mutants contain at most three amino acid substitutions, where X1 is N, S , V, T or P, and X2 is D, Y, C, H, S, R, A, E, G, K, W, V or Q includes one HC-CDR3 and the V L is RSSQSLLHSX1GYN YLD (SEQ ID NO:184) or its variants are included, and even if the number of the variants is large It contains three amino acid substitutions, where X1 is N, A, V, F, R, G, H, Q , one LC-CDR1 which is W or P, and LGSNRAS (SEQ ID NO: 5 1) or a variant thereof, wherein the variant contains at most three amino acid substitutions. One LC-CDR2 and MQALQTPX1T (SEQ ID NO:214) This includes the variant, and the aforementioned variant contains at most three amino acid substitutions, and here Therefore, X1 is an isolated anti-Psl antibody containing one LC-CDR3, which is either R or Y. To provide.

[0210] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:13 and amino acid sequence SEQ ID N Contains one HC-CDR3 containing O:24, or at most five HC-CDRs Includes a variant containing an amino acid substitution, and V L This is the amino acid sequence SEQ ID NO:37 One LC-CDR1 containing and one L containing amino acid sequence SEQ ID NO:51 C-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0211] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:13 and amino acid sequence SEQ ID N Includes one HC-CDR3 containing O:24, and the V L This is the amino acid sequence SEQ ID One LC-CDR1 containing NO:37 and amino acid sequence SEQ ID NO:51 It contains one LC-CDR2 and one LC containing amino acid sequence SEQ ID NO:62 -Includes CDR3. In some embodiments, V H and V L Including the above V H teeth, One HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence SE One HC-CDR2 containing Q ID NO:13 and amino acid sequence SEQ ID NO Includes one HC-CDR3 containing :24, and the V L This is the amino acid sequence SEQ ID Contains one LC-CDR1 including NO:37 and amino acid sequence SEQ ID NO:51 One LC-CDR2 and one LC- containing amino acid sequence SEQ ID NO:62 This invention provides an anti-Psl antibody that specifically competes with antibodies containing CDR3. Several examples illustrate this. V H and V L Including the above V H It contains amino acid sequence SEQ ID NO:1 One HC-CDR1 and one HC- containing amino acid sequence SEQ ID NO:13 It contains CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:24. M, the aforementioned V L It contains one LC-CDR1 with amino acid sequence SEQ ID NO:37 and , one LC-CDR2 containing amino acid sequence SEQ ID NO:51, and amino acid sequence One LC-CDR3 containing SEQ ID NO:62 and the same epitope as the antibody It provides a binding anti-Psl antibody.

[0212] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:79, or amino acid sequence SEQ ID NO:7 9 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%, 9) The variant sequence has sequence identity of 6%, 97%, 98%, or 99%, and the V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID NO: 91 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) It contains variant sequences with 96%, 97%, 98%, or 99% sequence identity. In that embodiment, the anti-Psl antibody contains amino acid sequence SEQ ID NO:79 Mu V H And V containing amino acid sequence SEQ ID NO:91 L This includes several implementations. In the example, the anti-Psl antibody is V H and V L Including the above V H The amino acid sequence S V with EQ ID NO:79 H HC-CDR1, HC-CDR2 and H Includes C-CDR3, and the V L This is a V with amino acid sequence SEQ ID NO:91. L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0213] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:170, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0214] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:170, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:170, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:170 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as containing one LC-CDR3 with amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0215] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 128, or amino acid sequence SEQ ID NO: 128 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:12 V including 8 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:128 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0216] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:171, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0217] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:171, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:171, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:171 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as containing one LC-CDR3 with amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0218] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:129, or amino acid sequence SEQ ID NO: 129 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:12 V including 9 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:129 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0219] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:172, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V LThe amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0220] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:172, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:172, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:172 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0221] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:130, or amino acid sequence SEQ ID NO: 130 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 0 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is VH and V L Including the above V H amino acids V with sequence SEQ ID NO:130 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0222] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID It contains one HC-CDR3 containing NO:173, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0223] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:173, and the VL This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:173, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:173 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0224] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:131, or amino acid sequence SEQ ID NO: 131 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V containing 1 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:131 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0225] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Contains one HC-CDR3 containing NO:36, or at most five HC-CDRs The variant includes the amino acid substitution of the V L This is the amino acid sequence SEQ ID NO:3 One LC-CDR1 containing 7 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This includes, or includes mutants in which LC-CDRs have at most 5 amino acid substitutions.

[0226] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:36, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:37 and amino acid sequence SEQ ID NO:51 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:62 Includes C-CDR3. In some examples, V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:36, and the V L This is the amino acid sequence SEQ I One LC-CDR1 containing D NO:37 and amino acid sequence SEQ ID NO:51 One LC-CDR2 containing and one L containing amino acid sequence SEQ ID NO:62 The present invention provides an anti-Psl antibody that specifically competes with antibodies containing C-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO:1 One HC-CDR1 containing and one amino acid sequence SEQ ID NO:163 HC-CDR2 and one HC-CDR3 containing amino acid sequence SEQ ID NO:36 and the V L This is one LC-CD containing amino acid sequence SEQ ID NO:37 R1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, and amino The antibody containing one LC-CDR3 with acid sequence SEQ ID NO:62 and the same epithelium This provides an anti-Psl antibody that binds to the pyogenes.

[0227] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 132, or amino acid sequence SEQ ID NO: 132 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 2 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:132 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0228] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:174, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0229] In some examples, the anti-Psl antibody is V H and V L Including the above VH teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:174, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:174, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:174 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0230] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:133, or amino acid sequence SEQ ID NO: 133 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 3 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:133 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0231] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:175, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0232] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:175, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:175, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:175 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0233] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:134, or amino acid sequence SEQ ID NO: 134 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 4 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:134 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0234] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:176, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0235] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:176, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:176, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:176 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0236] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:135, or amino acid sequence SEQ ID NO: 135 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 5 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:135H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0237] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:177, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0238] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:177, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:177, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:177 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0239] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:136, or amino acid sequence SEQ ID NO: 136 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 6 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:136 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0240] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:178, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0241] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:178, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:178, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:178 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0242] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO: 137, or amino acid sequence SEQ ID NO: 137 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 7 H And V containing amino acid sequence SEQ ID NO:91L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:137 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0243] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:179, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0244] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:179, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:179, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:179 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0245] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:138, or amino acid sequence SEQ ID NO: 138 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 8 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:138 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0246] In some examples, the anti-Psl antibody is V H and V L Including the above V Hteeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:180, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 37 and one containing amino acid sequence SEQ ID NO:51 LC-CDR2 and one LC-CDR containing amino acid sequence SEQ ID NO:62 3. Includes, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions.

[0247] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:180, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37 and amino acid sequence SEQ ID NO:5 One LC-CDR2 containing 1 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H This includes one HC-CDR1 containing the amino acid sequence SEQ ID NO:1, and the amino acid sequence One HC-CDR2 containing SEQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:180, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:37, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with antibodies containing LC-CDR3. In the example, V H and V L Including the above V H This is the amino acid sequence SEQ ID NO :1 contains one HC-CDR1 and 1 contains amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC-C containing amino acid sequence SEQ ID NO:180 Including DR3, the V L This is one LC containing amino acid sequence SEQ ID NO:37 -CDR1 and one LC-CDR2 containing amino acid sequence SEQ ID NO:51, The same antibody as one LC-CDR3 containing amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that binds to an epitope.

[0248] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:139, or amino acid sequence SEQ ID NO: 139 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:91, or amino acid sequence SEQ ID N O:91 and at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%) It includes variant sequences with sequence identity of %, 96%, 97%, 98%, or 99%. In several examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO:13 V including 9 H And V containing amino acid sequence SEQ ID NO:91 L This includes several. In the example, the anti-Psl antibody is V H and V L Including the above V H amino acids V with sequence SEQ ID NO:139 H HC-CDR1, HC-CDR2 and HC-CDR3, and the V L It has amino acid sequence SEQ ID NO:91 do V L This includes LC-CDR1, LC-CDR2, and LC-CDR3.

[0249] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:182, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 191 and one containing amino acid sequence SEQ ID NO:51 One LC-CDR2 and one LC-CD containing amino acid sequence SEQ ID NO:62 Includes R3, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions. .

[0250] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:182, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:191, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, V H and V L Including the above V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:1, and amino acid One HC-CDR2 containing sequence SEQ ID NO:163 and amino acid sequence SEQ I D NO:182 includes one HC-CDR3 and the V L This is the amino acid sequence SE One LC-CDR1 containing Q ID NO:191 and amino acid sequence SEQ ID N One LC-CDR2 containing O:51 and amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with an antibody containing one LC-CDR3. In that embodiment, V H and V L Including the above V H This is the amino acid sequence SEQ ID Contains one HC-CDR1 with NO:1 and amino acid sequence SEQ ID NO:163 One HC-CDR2 and one HC containing amino acid sequence SEQ ID NO:182 -Includes CDR3 and the VL This is one containing amino acid sequence SEQ ID NO:191 LC-CDR1 and one LC-CDR containing amino acid sequence SEQ ID NO:51 An antibody containing 2 and one LC-CDR3 with amino acid sequence SEQ ID NO:62. This provides an anti-Psl antibody that binds to the same epitope.

[0251] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , amino acid sequence SEQ ID NO:151, or amino acid sequence SEQ ID NO: 151 and at least 90% (for example, at least 91%, 92%, 93%, 94%, 95%) The mutant sequence having sequence identity of 96%, 97%, 98%, or 99%, is described above. V L This refers to amino acid sequence SEQ ID NO:140, or amino acid sequence SEQ ID NO:140 and at least 90% (for example, at least 91%, 92%, 93%, 94%) Includes variant sequences with sequence identity of 95%, 96%, 97%, 98%, or 99%. In some examples, the anti-Psl antibody has the amino acid sequence SEQ ID NO: V including 151 H And V containing amino acid sequence SEQ ID NO:140 L It includes. In several examples, the anti-Psl antibody was V H and V L Including the above V H is, V with mino acid sequence SEQ ID NO:151 H HC-CDR1, HC-C Including DR2 and HC-CDR3, the V L This is the amino acid sequence SEQ ID NO:1 V with 40L Includes LC-CDR1, LC-CDR2, and LC-CDR3 in .

[0252] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:182, or at most 5 HC-CDRs. The variant includes a variant containing a number of amino acid substitutions, and the V L The amino acid sequence SEQ ID NO: One LC-CDR1 containing 192 and one containing amino acid sequence SEQ ID NO:51 One LC-CDR2 and one LC-CD containing amino acid sequence SEQ ID NO:62 Includes R3, or includes mutants in which LC-CDRs have at least 5 amino acid substitutions. .

[0253] In some examples, the anti-Psl antibody is V H and V L Including the above V H teeth , one HC-CDR1 containing amino acid sequence SEQ ID NO:1, and amino acid sequence S One HC-CDR2 containing EQ ID NO:163 and amino acid sequence SEQ ID Includes one HC-CDR3 containing NO:182, and the V L This is the amino acid sequence SEQ One LC-CDR1 containing ID NO:192, and amino acid sequence SEQ ID NO: One LC-CDR2 containing 51 and one containing amino acid sequence SEQ ID NO:62 Includes LC-CDR3. In some embodiments, VH and V L Including the above V H It contains one HC-CDR1 with amino acid sequence SEQ ID NO:1, and amino acid One HC-CDR2 containing sequence SEQ ID NO:163 and amino acid sequence SEQ I D NO:182 includes one HC-CDR3 and the V L This is the amino acid sequence SE One LC-CDR1 containing Q ID NO:192 and amino acid sequence SEQ ID N One LC-CDR2 containing O:51 and amino acid sequence SEQ ID NO:62 This provides an anti-Psl antibody that specifically competes with an antibody containing one LC-CDR3. In that embodiment, V H and V L Including the above V H This is the amino acid sequence SEQ ID Contains one HC-CDR1 with NO:1 and am...

Claims

1. (i) V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 13, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 24, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (ii) V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 171, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (iii) V Ｈ and V Ｌ comprising, wherein said V Ｈ comprises one HC-CDR1 consisting of the amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of the amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of the amino acid sequence SEQ ID NO: 172, and said V Ｌ comprises one LC-CDR1 consisting of the amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of the amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of the amino acid sequence SEQ ID NO: 62, (iv) V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 173, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (v)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 36, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (vi)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 174, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (vii) V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 175, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (viiii)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 176, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (ix)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 177, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (x)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 178, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (xi)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 179, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (xi)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 180, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (xiiii)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 13, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 181, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (xiv) V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 182, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. (xv)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 185, and the V Ｌ This comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO: 62, or (xvi)V Ｈ and V Ｌ Including the above V Ｈ It comprises one HC-CDR1 consisting of amino acid sequence SEQ ID NO: 1, one HC-CDR2 consisting of amino acid sequence SEQ ID NO: 163, and one HC-CDR3 consisting of amino acid sequence SEQ ID NO: 186, and the V Ｌ It comprises one LC-CDR1 consisting of amino acid sequence SEQ ID NO: 37, one LC-CDR2 consisting of amino acid sequence SEQ ID NO: 51, and one LC-CDR3 consisting of amino acid sequence SEQ ID NO:

62. An isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl.

2. (i) V Ｈ and V Ｌ Including the above V Ｈ This includes the amino acid sequence SEQ ID NO: 79, or a mutant sequence having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 79, and the V Ｌ This includes amino acid sequence SEQ ID NO: 91, or a variant sequence having at least 90% sequence identity with amino acid sequence SEQ ID NO: 91, or (ii) V Ｈ and V Ｌ Including the above V Ｈ This includes one amino acid sequence of any one of SEQ ID NOs: 129-139, SEQ ID NO: 149, SEQ ID NO: 151, and SEQ ID NOs: 154-155, or a mutant sequence having at least 90% sequence identity with one of the amino acid sequences of any one of SEQ ID NOs: 129-139, SEQ ID NO: 149, SEQ ID NO: 151, and SEQ ID NOs: 154-155, and the V Ｌ This includes amino acid sequence SEQ ID NO: 91, or a mutant sequence having at least 90% sequence identity with amino acid sequence SEQ ID NO:

91. An isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl as described in claim 1.

3. The antibody or antigen-binding fragment comprises an Fc fragment and is an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl as described in claim 1 or 2.

4. The antibody or antigen-binding fragment is a full-length IgG antibody, and is an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl according to claim 3.

5. The antibody or antigen-binding fragment is a full-length IgG1 or IgG4 antibody, wherein the isolated antibody or antigen-binding fragment specifically binds to Pseudomonas Psl according to claim 4.

6. The antibody or antigen-binding fragment is a chimeric antibody or a human antibody, and is an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl according to any one of claims 1 to 5.

7. The antibody or antigen-binding fragment is an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl as described in claim 1 or 2, selected from the group consisting of Fab, Fab', F(ab)'2, Fab'-SH, single-chain antibody (scFv), Fv fragment, and diabody.

8. An isolated nucleic acid molecule encoding an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl as described in any one of claims 1 to 7.

9. A vector comprising the nucleic acid molecule described in claim 8.

10. An isolated host cell comprising an antibody or antigen-binding fragment according to any one of claims 1 to 7, a nucleic acid molecule according to claim 8, or a vector according to claim 9.

11. a) Culturing the host cells described in claim 10 under conditions that effectively express an anti-Psl antibody or antigen-binding fragment, and b) A method for preparing an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl, comprising obtaining an expressed anti-Psl antibody or antigen-binding fragment from host cells.

12. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment that specifically binds to a Pseudomonas Psl as described in any one of claims 1 to 7, a nucleic acid molecule as described in claim 8, a vector as described in claim 9, or an isolated host cell as described in claim 10, and a pharmaceutically acceptable carrier.

13. The use of an isolated antibody or antigen-binding fragment that specifically binds to Pseudomonas Psl according to any one of claims 1 to 7, a nucleic acid molecule according to claim 8, a vector according to claim 9, an isolated host cell according to claim 10, or a pharmaceutical composition according to claim 12 in the preparation of a drug for treating a disease or condition in an individual in need, The aforementioned disease or condition is a Pseudomonas aeruginosa infection.

14. The use according to claim 13, wherein the disease or symptom includes one or more symptoms caused by Pseudomonas aeruginosa infection.

15. The use according to claim 14, wherein the symptoms include one or more of the following: fever, chills, fatigue, muscle and joint pain, joint swelling, headache, diarrhea, skin rash, wound pus, bacteremia, acute pneumonia, intraperitoneal infection, respiratory infection, septic shock, suppurative arthritis, enteritis, skin and soft tissue infection, urinary tract infection, intestinal infection, ulcerative keratitis, chronic suppurative otitis media, mastoiditis, sinusitis, and endocarditis.

16. The use according to any one of claims 13 to 15, wherein the isolated antibody or antigen-binding fragment that specifically binds to the Pseudomonas Psl, the nucleic acid molecule, the vector, the isolated host cell, or the pharmaceutical composition is intended to be administered in combination with an antibiotic.

17. The use according to claim 16, wherein the antibiotic is one or more of imipenem, tobramycin, ciprofloxacin, meropenem, and aztreonam.

Images